SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
(Amendment No.__)
Filed by the Registrant þ
Filed by a Party other than the Registrant ¨
Check the appropriate box:
¨ Preliminary Proxy Statement
¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
þ Definitive Proxy Statement
¨ Definitive Additional Materials
¨ Soliciting Material Pursuant to § 240.14a-12
SI-BONE, INC.
(Name of Registrant as Specified In Its Charter)
N/A
(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)
Payment of Filing Fee (Check all boxes that apply)
þ No fee required.
¨ Fee paid previously with preliminary materials.
¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
INVITATION TO 20222023 ANNUAL MEETING OF STOCKHOLDERS
DATE: Thursday,Friday, June 16, 20229, 2023
TIME: 8:0030 a.m., local timePacific Time
April 22, 202221, 2023
Dear Stockholders:
Please join me at theIt is my pleasure to invite you to attend SI-BONE's Annual Meeting of Stockholders (the "Annual Meeting") on Friday, June 9, 2023 at 8:30 a.m., Pacific Time. The attached Notice of SI-BONE, Inc. on June 16, 2022. This year,Annual Meeting of Stockholders and Proxy Statement will serve as your guide to the business we will be conducting a virtualconduct at the Annual Meeting.
We have made significant and measurable progress since last year’s annual meeting dueof stockholders, including the following:
•Achieved worldwide revenue of $106.4 million for the full year 2022, representing an increase of 18% over the year 2021
•Grew revenue 10%, 15%, 19% and 27% in Q1, Q2, Q3 and Q4, as compared with the prior year periods
•Surpassed 80,000 procedures performed by over 3,000 surgeons worldwide since inception
•Finished the year with over 920 active surgeons in the fourth quarter 2022, an approximately 33% increase over the prior year period
•Achieved gross margins of 85% for the full year 2022
•Launched iFuse Bedrock Granite®, designated by the FDA as a breakthrough device targeting adult spinal deformity and eligible for a New Technology Add-on Payment (NTAP) of up to $9,800 in Medicare procedures
•Received FDA clearance for promotion of general rod compatibility for iFuse Bedrock Granite for adult deformity procedures
•Expanded our indications for iFuse-TORQ® to include the continuing public health impactBedrock approach, allowing the promotion of coronavirus disease (COVID-19). YouiFuse-TORQ to complement iFuse-Bedrock Granite as a second point of fixation in the Sacro-Alar-Iliac trajectory, and for an expanded trauma indication which includes fixation of pelvic fragility and sacral insufficiency fractures
•Completed patient enrollment for SILVIA, a two-year prospective international multi-center randomized controlled trial of two different methods for pelvic fixation in adult patients
•Enrolled the first patient in SAFFRON, a prospective randomized clinical trial of surgery using iFuse-TORQ versus non-surgical management in patients with stable but debilitating sacral insufficiency fractures
We will not be ableonce again hold the Annual Meeting virtually in an effort to attend the meeting in person, but we do encouragemake it convenient for our stockholders participate into attend. During our annual meeting online by way of our live webcast as outlined in this proxy statement. At the annual meeting,Annual Meeting, we will askdiscuss each item of business described in the Notice of Annual Meeting and Proxy Statement enclosed with this letter, which we encourage you to:to read carefully. We will also address any questions submitted before or during the Annual Meeting.
1. ElectYour vote is very important to us, and I urge you to vote your shares as promptly as possible. You may vote by Internet or by telephone. If you received a paper copy of the Boardproxy card by mail, you may sign, date, and return the proxy card in the enclosed envelope.
Finally, I continue to be humbled by the exceptional performance of Directors’ three nominees, Timothy E. Davis, Jr., Laura A. Francisthe entire SI-BONE team, despite the unpredictable and Jeryl L. Hilleman, as directors servingunprecedented challenges we have faced in Class Ithe past several years. On behalf of the Board, of Directors of SI-BONE, eachmanagement team and employees, thank you for your continued confidence and support as we advance our mission to serve untilhelp patients rise up and reach for the next annual meeting in which directors in Class I shall be elected, or until a successor is duly elected and qualified;
2. Ratify the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2022;
3. Provide an advisory, non-binding vote on the compensation of our named executive officers, as disclosedstars. We look forward to your participation in this proxy statement;
4. Indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of our named executive officers; and
5. Conduct any other business properly brought before the meeting.
Members of the Board of Directors will also be present.
Whether or not you are able to attend the annual meeting by webcast, it is important that your shares be represented. We have provided in the accompanying proxy statement instructions on how to vote your shares. Please vote as soon as possible.year’s Annual Meeting.
Sincerely yours,
| | |
| /s/ Laura Francis |
| Laura Francis |
| Chief Executive Officer |
SI-BONE, INC.
471 El Camino Real, Suite 101
Santa Clara, California 95050
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
To Be Held on June 16, 20229, 2023
Dear Stockholder:
You are cordially invited to attend the virtual Annual Meeting of Stockholders of SI-BONE, Inc., a Delaware corporation. The meeting will be a completely virtual meeting of stockholders and will be held on Thursday,Friday, June 16, 20229, 2023 at 8:0030 a.m. local timePacific Time by live webcast as described in the proxy statement accompanying this notice. The Annual Meeting is being held for the following purposes:
1. To elect the Board of Director’s three nominees for director to serve until the 20252026 Annual Meeting of Stockholders or until their successors are elected and qualified.
2. To ratify the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022.2023.
3. To provide an advisory, non-binding vote on the compensation of our named executive officers, as disclosed in this proxy statement.
4. To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of our named executive officers.
5. To conduct any other business properly brought before the meeting.
These items of business are more fully described in the Proxy Statement accompanying this notice.
You will be able to attend the virtual Annual Meeting and submit your questions and vote your shares online during the meeting by visiting www.virtualshareholdermeeting.com/SIBN2022SIBN2023 and using your 16-digit control number to enter the virtual Annual Meeting. If you determine to attend the Annual Meeting by webcast, you will only be able to participate by using your 16-digit control number provided on the proxy or information card to enter the Annual Meeting. Without your 16-digit control number, you will only be able to enter as a guest in listen-only mode and will not be able to vote. Therefore, it is important to retain a copy of your proxy or information card you receive to enable you to gain participation access to the virtual Annual Meeting.
The stockholder list will also be available during the Annual Meeting at www.virtualshareholdermeeting.com/SIBN2022.SIBN2023. Instructions on how stockholders of record can view the stockholder list during the Annual Meeting are posted at www.virtualshareholdermeeting.com/SIBN2022.SIBN2023. The record date for the Annual Meeting is April 18, 2022.14, 2023. Only stockholders of record at the close of business on that date may vote at the meeting or any adjournment thereof.
Important Notice Regarding the Availability of Proxy Materials for the 20222023 Stockholders’ Meeting to Be Held on June 16, 20229, 2023 via live webcast at www.virtualshareholdermeeting.com/SIBN2022.SIBN2023. You will need the 16-digit control number provided on the proxy or information card in order to gain access to the Annual Meeting by live webcast.
The proxy statement and annual report to stockholders
are available at www.proxyvote.com.
By Order of the Board of Directors
| | |
| /s/ Michael A. Pisetsky |
| Michael A. Pisetsky |
Secretary and Chief Legal OfficerGeneral Counsel |
Santa Clara, California
April 22, 2022
You are cordially invited to attend the meeting by live webcast as described in the proxy statement accompanying this notice. Whether or not you expect to attend the meeting, please vote as soon as possible in order to ensure your representation at the meeting. You may vote over the internet or by a toll-free telephone number, or you may vote by mailing a completed, signed and dated proxy card or voting instruction card in the envelope provided with the proxy card or voting instruction card. Please note that any stockholder attending the virtual Annual Meeting may vote online during the meeting, even if the stockholder has already returned a proxy card or voting instruction card. Please see the instructions in the attached proxy statement and on your proxy card or voting instruction card.
SI-BONE, Inc.
471 El Camino Real, Suite 101
Santa Clara, California 95050
PROXY STATEMENT
FOR THE 20222023 ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON JUNE 16, 20229, 2023
IMPORTANT NOTICE REGARDING THE INTERNET AVAILABILITY OF PROXY MATERIALS
FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JUNE 16, 20229, 2023
This proxy statement and our 20222023 Annual Report to Stockholders, which includes our Annual Report on Form 10-K for the fiscal year ended December 31, 2021,2022, are available on our website at https://investor.si-bone.com/financial-information/annual-reports and www.proxyvote.com. We intend to mail these proxy materials on or about April 22, 202227, 2023 to all stockholders of record entitled to vote at the annual meeting.Annual Meeting.
MEETING AGENDA
| | | | | | | | | | | | | | | | | | | | | |
| Proposal Number | | Proposal | | Vote Required for Approval | | | | |
| 1 | | To elect the Board of Directors' three nominees for director to serve until the 20252026 Annual Meeting of Stockholders or until their successors are elected and qualified. | | The three nominees receiving the most “For” votes will be elected; withheld votes will have no effect
| | | | |
| 2 | | To ratify the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022.2023. | | “For” votes from the holders of a majority of shares present, via webcast or represented by proxy and entitled to vote on the matter | | | | |
| 3 | | To provide an advisory non-binding vote on the compensation of our named executive officers, as disclosed in this proxy statement. | | “For” votes from the holders of a majority of shares present via webcast or represented by proxy and entitled to vote on the matter. | | | | |
| 4 | | To indicate, on an advisory basis, the frequency of stockholder advisory votes on executive compensation | | The frequency receiving “For” votes from the holders of a majority of shares present via webcast or represented by proxy and entitled to vote on the matter will be the frequency approved. | | | | |
| | | | | | | | | |
QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING
Why am I receiving these materials?
We have sent you these proxy materials because our Board of Directors (the “Board” or “Board of Directors”) is soliciting your proxy to vote at the 20222023 Annual Meeting of Stockholders, including at any adjournments or postponements of the meeting. You are invited to attend the virtual annual meetingAnnual Meeting to vote on the proposals described in this proxy statement. However, you do not need to attend the meeting to vote your shares. Instead, you may simply complete, sign and return the enclosed proxy card, or follow the instructions below to submit your proxy over the telephone or on the internet.
We intend to mail these proxy materials on or about April 22, 202227, 2023 to all stockholders of record entitled to vote at the annual meeting.Annual Meeting.
What is included in the proxy materials?
The proxy materials include:
•This proxy statement, which includes information regarding the proposals to be voted on at the Annual Meeting, the voting process, corporate governance, the compensation of our directors and certain executive officers, and other required information;
•Our 20212022 Annual Report to Stockholders, which is our Annual Report on Form 10-K for the fiscal year endedending December 31, 2021;2022; and
•The proxy card or a voting instruction card for the Annual Meeting.
How do I attend the annual meeting?Annual Meeting?
The annual meetingAnnual Meeting will be held on Thursday,Friday, June 16, 20229, 2023 at 8:0030 a.m. local timePacific Time by live webcast. There will not be a physical meeting location and you will not be able to attend the meeting in personin-person physically. We invite you to attend the annual meetingAnnual Meeting by live webcast. The live audio webcast will be held on Thursday, June 16, 2022, and will begin promptly at 8:00 a.m. local time. Online check-in will begin approximately 15 minutes prior to the start of the Annual Meeting. We encourage our stockholders to access the meeting in advance of the designated start time to have ample time for check-in procedures. To attend the Annual Meeting virtually via the internet, please visit www.virtualshareholdermeeting.com/SIBN2022.SIBN2023. To attend by live webcast you will need the 16-digit control number provided on the proxy or information card you receive in order to gain access to the annual meeting.Annual Meeting. Therefore, it is important to retain a copy of your proxy or information card you receive to enable you to gain access to the annual meeting.Annual Meeting. However, as noted above, you do not need to attend the annual meetingAnnual Meeting to vote your shares. Instead, you may simply complete, sign and return a proxy card, or follow the instructions below to submit your proxy over the telephone or on the internet.
If you do not have your 16-digit control number, you will be able to access and listen to the Annual Meeting, but you will not be able to vote your shares or submit questions during the Annual Meeting. See caption below titled “Attending the Annual Meeting as a Guest.”
Attending the Annual Meeting as a Guest
Guests may enter the Annual Meeting in “listen-only” mode by entering the Annual Meeting at www.virtualshareholdermeeting.com/SIBN2021SIBN2023 and entering the information requested in the “Guest Login” section. Guests will not have the ability to vote at the Annual Meeting.
Why is SI-BONE having a virtual Annual Meeting?
Due to the continuing public health concerns regarding the COVID-19 outbreak and to assist in protecting the health and well-being of our stockholders and employees andTo facilitate stockholder participation in the Annual Meeting, this year’s annual meetingAnnual Meeting of our stockholders will be held virtually via the internet. Stockholders attending virtually via the internet will be able to listen and vote regardless of location via the internet at www.virtualshareholdermeeting.com/SIBN2022SIBN2023 by using the 16-digit control number included on your proxy card or information card and the instructions that accompanied your proxy materials.
Who can vote at the annual meeting?Annual Meeting?
Only stockholders of record at the close of business on April 18, 202214, 2023 will be entitled to vote at the annual meeting.Annual Meeting. On this record date, there were 33,883,545 shares35,138,820 shares of common stock outstanding and entitled to votevote.
Stockholder of Record: Shares Registered in Your Name
If on April 18, 2022,14, 2023, your shares were registered directly in your name with our transfer agent, American Stock Transfer & Trust Company, LLC, then you are a stockholder of record. As a stockholder of record, you may vote via webcast at the meeting or vote by proxy. Whether or not you plan to attend the meeting via webcast, we urge you to fill out and return the enclosed proxy card or vote by proxy over the telephone or on the internet as instructed below to ensure your vote is counted.
Beneficial Owner: Shares Registered in the Name of a Broker or Bank
If on April 18, 2022,14, 2023, your shares were held, not in your name, but rather in an account at a brokerage firm, bank or other similar organization, then you are the beneficial owner of shares held in “street name” and these proxy materials are being forwarded to you by that organization. The organization holding your account is considered to be the stockholder of record for purposes of voting at the annual meeting.Annual Meeting. As a beneficial owner, you have the right to direct your broker, bank or other agent regarding how to vote the shares in your account. You are also invited to attend the annual meeting.Annual Meeting. Many stockholders of record will provide you with a 16-digit control number via email or in your Notice of Availability or voting instruction form in order to attend and vote your shares at the virtual Annual Meeting. If you did not receive a 16-digit control number via email or on your Notice of Availability or voting instruction form, you will be provided with other instructions from your broker, bank or other stockholder of record that must be followed, including any requirement to obtain a valid legal proxy, in order for your broker, bank or other stockholder of record to vote your shares per your instructions or to attend and vote your shares at the Annual Meeting. Many brokers, banks or other stockholders of record allow a stockholder to obtain a valid legal proxy either online or by mail, and we recommend that you contact your broker, bank or other stockholder of record to do so.
Who can ask questions at the Annual Meeting?
If you are attending the Annual Meeting as a stockholder of record or as a beneficial owner, questions can be submitted by accessing the meeting center at www.virtualshareholdermeeting.com/SIBN2022,SIBN2023, entering your 16-digit control number and following the instructions. Instructions on how to ask questions and participate in the Annual Meeting are posted at www.virtualshareholdermeeting.com/SIBN2022.SIBN2023. Guests will not have the ability to ask questions during the Annual Meeting.
List of Stockholders
A list of stockholders entitled to vote at the Annual Meeting will be available for examination for any purpose germane to the Annual Meeting during normal business hours for ten days prior to the Annual Meeting at our corporate headquarters. Due to the COVID-19 pandemic, pleasePlease email us at StockholderCommunications@si-bone.com to arrange a time to review. The stockholder list will also be available during the Annual Meeting at www.virtualshareholdermeeting.com/SIBN2022.SIBN2023. Instructions on how stockholders of record can view the stockholder list during the Annual Meeting are posted at www.virtualshareholdermeeting.com/SIBN2022.SIBN2023.
What am I voting on?
There are fourthree matters scheduled for a vote:
•Election of three directors (Proposal No. 1);
•Ratification of selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as independent registered public accounting firm of SI-BONE for its fiscal year ending December 31, 20222023 (Proposal No. 2); and
•Advisory approval of the compensation of our named executive officers, as disclosed in this proxy statement in accordance with SEC rules (Proposal No. 3); and.
•Advisory indication of the preferred frequency of stockholder advisory votes on the compensation of our named executive officers (Proposal No. 4)
What if another matter is properly brought before the meeting?
The Board of Directors knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are properly brought before the meeting, it is the intention of the persons named in the accompanying proxy to vote on those matters, to the extent permitted under Rule 14a-4(c)(1) under the Exchange Act, in accordance with their best judgment.
How do I vote?
You may either vote “For” all of the nominees to the Board of Directors or you may “Withhold” your vote for any nominee you specify. For the ratification of selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as independent registered public accounting firm of SI-BONE for its fiscal year ending December 31, 2022,2023, and the advisory approval of the compensation of our named executive officers, as disclosed in this proxy statement in accordance with SEC rules, you may vote “For” or “Against” or abstain from voting. With regard to your advisory vote on how frequently we should solicit stockholder advisory approval of executive compensation, you may vote for any one of the following: one year, two years or three years, or you may abstain from voting on that matter. For any of the other matters to be voted on, you may vote “For” or “Against” or abstain from voting.
The procedures for voting are fairly simple:
Stockholder of Record: Shares Registered in Your Name
If you are a stockholder of record, you may vote via webcast at the annual meeting,Annual Meeting, vote by proxy using the enclosed proxy card, vote by proxy over the telephone, or vote by proxy through the internet. Whether or not you plan to attend the meeting, we urge you to vote by proxy to ensure your vote is counted. You may still attend the meeting and vote via webcast even if you have already voted by proxy.
•To vote during the meeting at the live webcast, if you are a stockholder of record as of the record date, follow the instructions at www.virtualshareholdermeeting.com/SIBN2022.SIBN2023. You will need the 16-digit control number provided on the proxy card in order to gain access to the annual meetingAnnual Meeting via webcast.
•To vote using the proxy card, simply complete, sign and date the enclosed proxy card and return it promptly in the envelope provided. If you return your signed proxy card to us before the annual meeting,Annual Meeting, we will vote your shares as you direct.
•To vote over the telephone, dial toll-free 1-800-690-6903 using a touch-tone phone and follow the recorded instructions. You will be asked to provide the control number from the enclosed proxy card. Your telephone vote must be received by 11:8:59 p.m., EasternPacific Time on June 15, 2022,8, 2023, to be counted.
•To vote through the internet, go to www.proxyvote.com to complete an electronic proxy card. You will be asked to provide control number from the enclosed proxy card. Your internet vote must be received by 11:8:59 p.m. Eastern, Pacific Time on June 15, 20228, 2023 to be counted.
Beneficial Owner: Shares Registered in the Name of Broker or Bank
If you are a beneficial owner of shares registered in the name of your broker, bank or other agent, you should have received a voting instruction form with these proxy materials from that organization rather than from us. Simply complete and mail the voting instruction form to ensure that your vote is counted. Alternatively, you may vote by telephone or over the internet as instructed by your broker or bank. To vote at the live webcast, you may be able to do so if your broker has provided you with a 16-digit control number, or if you have otherwise received a valid proxy. See “Who can vote at the annual meeting?Annual Meeting? - Stockholder of Record: Shares Registered in Your Name” above. To receive a valid proxy, follow the instructions from your broker or bank included with these proxy materials, or contact your broker or other agent to request a proxy form.
Internet proxy voting may be provided to allow you to vote your shares online, with procedures designed to ensure the authenticity and correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your internet access, such as usage charges from internet access providers and telephone companies.
How many votes do I have?
On each matter to be voted upon, you have one vote for each share of common stock you owned as of April 18, 2022.14, 2023.
If I am a stockholder of record and I do not vote, or if I return a proxy card or otherwise vote without giving specific voting instructions, what happens?
If you are a stockholder of record and do not vote by completing your proxy card, by telephone, through the internet or via webcast at the annual meeting,Annual Meeting, your shares will not be voted.
If you return a signed and dated proxy card or otherwise vote without marking voting selections, your shares will be voted, as applicable, “For” the election of all of the nominees for director, “For” the ratification of selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as independent registered public accounting firm of SI-BONE for its fiscal year ending December 31, 2022,2023, and “For” the advisory approval of the compensation of our named executive officers, as disclosed in this proxy statement in accordance with SEC rules, and for “one year” on how frequently we should solicit stockholder advisory approval of executive compensation.rules. If any other matter is properly presented at the meeting, your proxy holder (one of the individuals named on your proxy card) will vote your shares using his or her best judgment.
If I am a beneficial owner of shares held in street name and I do not provide my broker or bank with voting instructions, what happens?
If you are a beneficial owner of shares held in street name and you do not instruct your broker, bank or other agent how to vote your shares, your broker, bank or other agent may still be able to vote your shares in its discretion. In this regard, under the rules of the New York Stock Exchange (“NYSE”), brokers, banks and other securities intermediaries that are subject to NYSE rules may use their discretion to vote your “uninstructed” shares with respect to matters considered to be “routine” under NYSE rules, but not with respect to “non-routine” matters. In this regard, Proposals 1 3 and 43 are considered to be “non-routine” under NYSE rules meaning that your broker may not vote your shares on those proposals in the absence of your voting instructions. However, Proposal 2 is considered to be a “routine” matter under NYSE rules meaning that if you do not return voting instructions to your broker by its deadline, your shares may be voted by your broker in its discretion on Proposal 2.
Who is paying for this proxy solicitation?
We will pay for the entire cost of soliciting proxies. In addition to these proxy materials, our directors and employees may also solicit proxies in person, by telephone, or by other means of communication. Directors and employees will not be paid any additional compensation for soliciting proxies. We may also reimburse brokerage firms, banks and other agents for the cost of forwarding proxy materials to beneficial owners.
What does it mean if I receive more than one set of proxy materials?
If you receive more than one set of proxy materials, your shares may be registered in more than one name or in different accounts. Please follow the voting instructions on the proxy cards in the proxy materials to ensure that all of your shares are voted.
Can I change my vote after submitting my proxy?
Stockholder of Record: Shares Registered in Your Name
Yes. You can revoke your proxy at any time before the final vote at the meeting. If you are the record holder of your shares, you may revoke your proxy in any one of the following ways:
•You may submit another properly completed proxy card with a later date.
•You may grant a subsequent proxy by telephone or through the internet.
•You may send a timely written notice that you are revoking your proxy to the attention of our Chief Legal OfficerGeneral Counsel and Secretary at 471 El Camino Real, Suite 101, Santa Clara, California 95050.
•You may attend the annual meetingAnnual Meeting and vote via webcast. Simply attending the meeting will not, by itself, revoke your proxy.
Your most current proxy card or telephone or internet proxy is the one that is counted.
Beneficial Owner: Shares Registered in the Name of Broker or Bank
If your shares are held by your broker, bank or other agent, you should follow the instructions provided by your broker, bank or other agent, or you may attend the virtual annual meetingAnnual Meeting and vote online. Simply attending the meeting will not, by itself, revoke your proxy.
When are Stockholder proposals due for next year’s annual meeting?
To be considered for inclusion in next year’s proxy materials, your proposal must be submitted in writing by December 23, 2022,29, 2023, to SI-BONE, Inc., Attn: Michael A. Pisetsky, Chief Legal Officer,General Counsel, 471 El Camino Real, Suite 101, Santa Clara, California 95050; provided, however, that if the 20232024 annual meeting of stockholders is held before May 17, 202310, 2024 or after July 16, 2023,9, 2024, then your proposal must be submitted in writing a reasonable amount of time before the 20232024 annual meeting of stockholders.
If you wish to submit a proposal (including a director nomination) at the meeting that is not to be included in next year’s proxy materials, your proposal must be submitted in writing and received by our Secretary at our executive offices located at 471 El Camino Real, Suite 101, Santa Clara, California 95050, not later than the close of business on March 18, 2023,11, 2024, nor earlier than the close of business on February 16, 2023;10, 2024; provided, however, that in the event that the date of the annual meeting is held earlier than May 17, 2023,10, 2024, or held later than July 16, 2023,9, 2024, notice by the stockholder to be timely must be so received notno earlier than the close of business on the one hundred twentieth (120th) day prior to such annual meeting and not later than the close of business on the later of the ninetieth (90th) day prior to such annual meeting or the tenth (10th) day following the day on which public announcement of the date of such meeting is first made.
In addition, to comply with the universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than our nominees must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act no later than April 10, 2024; provided, however, that, in the event that the Annual Meeting is held before May 10, 2024, or after July 9, 2024, for your notice to be timely, it must be so received by the Secretary not earlier than the close of business on the date the later of sixty (60) days prior to such annual meeting and the tenth (10th) day following the day on which public announcement of the date of such meeting is first made by us.
Stockholders wishing to make stockholder proposals or nominations for directors should consult our bylaws and Rule 14a-19 under the Exchange Act, which contain additional requirements and information regarding these matters.
How are votes counted?
Votes will be counted by the inspector of election appointed for the meeting, who will separately count, (a) for the proposal to elect directors, votes “For,” votes “Withheld” and broker non-votes, (b) with respect to the ratification of selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as independent registered public accounting firm of SI-BONE for its fiscal year ending December 31, 2022,2023, and the advisory approval of the compensation of our named executive officers, as disclosed in this proxy statement in accordance with SEC rules, votes “For” and “Against,” abstentions and, if applicable, broker non-votes, (c) with respect to the proposal regarding frequency of stockholder advisory votes to approve executive compensation, votes for frequencies of one year, two years or three years, abstentions and broker non-votes, and (d)(c) for any other proposals, votes “For” and “Against,” abstentions and, if applicable, broker non-votes.
Abstentions will be counted towards the vote total for each of Proposals No. 2 and No. 3, and will have the same effect as “Against” votes. For Proposal 4, abstentions will be counted towards the vote total, and will have the same effect as votes against each of the proposed voting frequencies. Broker non-votes on Proposals 1 3 and 4 and3 will have no effect and will not be counted towards the vote total for any of those proposals. As Proposal No. 2 is a “routine” matter we do not expect there to be any broker non-votes, but if there are broker non-votes, they will have no effect and will not be counted towards the vote total for any proposal.total.
What are “broker non-votes”?
As discussed above, when a beneficial owner of shares held in street name does not give voting instructions to his or her broker, bank or other securities intermediary holding his or her shares as to how to vote on matters deemed to be “non-routine” under NYSE rules, the broker, bank or other such agent cannot vote the shares. These un-voted shares are counted as “broker non-votes.”
How many votes are needed to approve each proposal?
The following table summarizes the minimum vote needed to approve each proposal and the effect of abstentions and broker non-votes.
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| Proposal Number | | Proposal Description | | Vote Required for Approval | | Effect of Abstentions | | Effect of Broker Non-Votes |
| 1 | | Election of Directors | | The three nominees receiving the most “For” votes will be elected; withheld votes will have no effect
| | Not applicable | | No effect |
| 2 | | Ratification of the selection of PricewaterhouseCoopers LLP as SI-BONE’s independent registered public accounting firm for the fiscal year ending December 31, 20222023 | | “For” votes from the holders of a majority of shares present via webcast or represented by proxy and entitled to vote on the matter | | Against | | No effect |
| 3 | | Advisory vote on the compensation of our named executive officers | | “For” votes from the holders of a majority of shares present via webcast or represented by proxy and entitled to vote on the matter | | Against | | No effect |
4 | | Advisory vote on the frequency of stockholder advisory votes on executive compensation | | The frequency receiving the votes of the holders of a majority of shares present via webcast or represented by proxy and entitled to vote on the matter will be the frequency approved. | | Against each of the proposed voting frequencies | | No effect |
What is the quorum requirement?
A quorum of stockholders is necessary to hold a valid meeting. A quorum will be present if stockholders holding at least a majority of the outstanding shares entitled to vote are present at the meeting via webcast or represented by proxy. On the record date, there were 33,883,54535,138,820 shares outstanding and entitled to vote. Thus, the holders of 16,941,77317,569,410 shares must be present via webcast or represented by proxy at the meeting to have a quorum.
If you are a stockholder of record your shares will be counted towards the quorum only if you submit a valid proxy (or one is submitted on your behalf by your broker, bank or other nominee) or if you vote via webcast at the meeting. Abstentions and broker non-votes will be counted towards the quorum requirement. If there is no quorum, the chairman of the meeting or the holders of a majority of shares present at the meeting via webcast or represented by proxy may adjourn the meeting to another date.
How can I find out the results of the voting at the annual meeting?Annual Meeting?
Preliminary voting results will be announced at the annual meeting.Annual Meeting. In addition, final voting results will be published in a current report on Form 8-K that we expect to file within four business days after the annual meeting.Annual Meeting. If final voting results are not available to us in time to file a Form 8-K within four business days after the meeting, we intend to file a Form 8-K to publish preliminary results and, within four business days after the final results are known to us, file an additional Form 8-K to publish the final results.
What proxy materials are available on the internet?
The proxy statement and Annual Report to Stockholders are available at www.proxyvote.com.
PROPOSAL NO. 1
ELECTION OF DIRECTORS
Our Board of Directors is divided into three classes. Each class consists, as nearly as possible, of one-third of the total number of directors, and each class has a three-year term. Vacancies on the Board may be filled only by persons elected by a majority of the remaining directors. A director elected by the Board of Directors to fill a vacancy in a class, including vacancies created by an increase in the number of directors, shall serve for the remainder of the full term of that class and until the director’s successor is duly elected and qualified.
Our Board of Directors currently has nine members. There are three directors in Class I,II, the class the term of which expires in 2022: Timothy E. Davis, Jr., Laura A. Francis2023: Jeffrey W. Dunn, John G. Freund, M.D. and Jeryl L. Hilleman.Gregory K. Hinckley. Each is currently a member of our Board.Board of Directors. If elected at the annual meeting,Annual Meeting, each of the three nominees would serve until the 20252026 annual meeting and until his or her successor has been duly elected and qualified, or, if sooner, until the director’s death, resignation or removal. It is our policy to encourage directors and nominees for director to attend the Annual Meeting. All nine of our then-continuing directors and the nominees attended our 20212022 annual meeting of stockholders.
Each of Mr. Davis wasDunn, Dr. Freund and Mr. Hinckley were previously elected by our stockholders, and Ms. Francis is our Chief Executive Officer.stockholders.
Ms. Hilleman was recommended for nomination to the Nominating and Corporate Governance Committee by a number of our non-management directors.
Directors are elected by a plurality of the votes of the holders of shares present in person or represented by proxy and entitled to vote on the election of directors. Accordingly, the three nominees receiving the highest number of affirmative votes will be elected.
| | | | | | | | | | | |
| Name | Age | Position | Class |
Timothy “Ted” Davis, Jr | 52 | Lead Independent Director | I |
Laura A. Francis | 55 | CEO | I |
Jeryl L. Hilleman | 64 | Director | I |
| Jeffrey W. Dunn | 6768 | Executive Chairman | II |
| John G. Freund, M.D. | 6869 | Director | II |
| Gregory K. Hinckley | 7576 | Director | II |
| Helen Loh | 59 | Director | III |
| Mika Nishimura | 5859 | Director | III |
| Keith C. Valentine | 5455 | Director | III |
| Timothy "Ted" Davis | 52 | Lead Independent Director | I |
| Laura A. Francis | 56 | CEO | I |
| Jeryl L. Hilleman | 65 | Director | I |
The following is a brief biography of each nominee and each director whose term will continue after the annual meeting.Annual Meeting.
NOMINEES FOR ELECTION FOR A THREE-YEAR TERM EXPIRING AT THE 20252026 ANNUAL MEETING
Timothy E. Davis, Jr.Jeffrey W. Dunn has served as our Executive Chairman since April 2021, as Chairman of our Board of Directors since our inception in April 2008 until April 2021, and as our President and Chief Executive Officer from April 2008 until April 2021. Prior to joining us, Mr. Dunn served as Chief Executive Officer of INBONE Technologies, Inc., an ankle replacement and small bone fusion medical device company, from December 2006 to April 2008, until its sale to Wright Medical Technology, Inc. in April 2008. From August 2000 to June 2006, Mr. Dunn was the Chief Executive Officer of Active Decisions, Inc., a software as a service business, until its sale to Knova Software, Inc. From December 1999 to June 2000, Mr. Dunn was the Chief Executive Officer of Velogic, Inc., an internet performance testing software company, until its sale to Keynote Systems Inc. From June 1999 to December 1999, Mr. Dunn was the Chief Executive Officer of EnterpriseLink Inc., a provider of enterprise Internet enablement software, until its sale to Merant, Inc. From November 1994 to June 1998, Mr. Dunn was Chief Executive Officer of AccelGraphics Inc., a 3D graphics system supplier, until its sale to Evans and Sutherland Computer Corporation. As well, during his career, Mr. Dunn held executive positions with Evans and Sutherland, Cygnet Systems, Inc., Avnet, Inc. and Xerox Corporation. Mr. Dunn received a B.A. from Colgate University and an M.B.A. from Babson College. We believe Mr. Dunn’s experience in the industry, his prior role as our President and Chief Executive Officer, and his knowledge of our company enable him to make valuable contributions to our Board of Directors.
John G. Freund, M.D. has served as a member of our Board of Directors since our inceptionJanuary 2013. Dr. Freund founded Skyline Ventures, a venture capital firm, in April 2008. Mr. DavisOctober 1997 and has served as Presidenta Managing Director of Skyline since then. In 2016, Dr. Freund co-founded and was Chief Executive Officer of TissueTech,Arixa Pharmaceuticals, Inc. an antibiotic company, which was acquired by Pfizer in October 2020. Prior to joining Skyline, Dr. Freund served as Managing Director in the private equity group of Chancellor Capital Management, a private capital investment firm. In November 1995, Dr. Freund cofounded Intuitive Surgical, Inc., a privatelymedical device company, and served on its board of directors until March 2000. From 1988 to 1994, he held parentvarious positions at Acuson Corporation, a maker of ultrasound equipment that is now part of Siemens, most recently as Executive Vice President. Prior to joining Acuson, Dr. Freund was a general partner of Morgan Stanley Venture Partners from 1987 to 1988. From 1982 to 1988, Dr. Freund was at Morgan Stanley &
Co., an investment banking company, of Bio-Tissue, Inc. and Amniox Medical, Inc., which focuseswhere he co-founded the Healthcare Group in the Corporate Finance Department in 1983. Dr. Freund has served on the development and clinical applicationboard of human birth tissue-based products, since January 2022. From February 2017 through December 2021, Mr. Davis served as President and Chief Executive Officerdirectors of Active Implants, LLC, a company that provides orthopedic implant solutions. From January 2014 through September 2015, Mr. Davis served as Chief Executive Officereach of MicroPort Orthopedics,Collegium Pharmaceuticals, Inc., a multinational producerspecialty pharmaceutical company, and Sutro Biopharma, Inc., a biotechnology company, since February 2014. Dr. Freund also serves on the board of orthopedic products, followingdirectors of fourteen U.S. registered investment funds managed by affiliates of the purchaseCapital Group, Inc. He also previously served on the board of Wright Medical Group’s OrthoRecon Business in January 2014. From December 2006 to January 2014, Mr. Davis served indirectors of a number of executive positions for Wright Medical Technology,publicly traded companies, including Tetraphase Pharmaceuticals, Inc., a subsidiary of Wright Medical Group,biopharmaceutical company, Map Pharmaceuticals, Inc., including Presidenta biopharmaceutical company, MAKO Surgical Corp., a medical device company, Proteon Therapeutics, Inc., a biotechnology company, Concert Pharmaceuticals, Inc., a biopharmaceutical company and XenoPort, Inc., a biopharmaceutical company where he served as Chairman. Dr. Freund is a member of the OrthoRecon business. From 2004 to 2006, Mr. Davis was a Partner with MB Venture Partners, LLC, a medical technology and life sciences venture capital firm. From 1997 to 2004, Mr. Davis held various positions, ultimately serving as Vice President, with Vector Fund Management, a healthcare and life sciences focused venture capital fund. Early in his career, Mr. Davis worked inAdvisory Board for the healthcare management consulting and pharmaceutical industries. Mr. DavisHarvard Business School Healthcare Initiative. Dr. Freund received a B.E. degreeB.A. in Biomedical EngineeringHistory from Vanderbilt UniversityHarvard College, an M.D. from Harvard Medical School, and an M.B.A. from the J.L. Kellogg GraduateHarvard Business School, of Management at Northwestern University.where he was a Baker Scholar. We believe Mr. Davis’
Dr. Freund’s experience with medical device companies, his role in the venture capital industry, his experience in compensation matters, and his knowledge of our company enable him to make valuable contributions to our Board of Directors.
Laura A. Francis has served as our Chief Executive Officer and as a member of our Board of Directors since April 2021. Previously, she served as our Chief Operating Officer from July 2019 to April 2021, and as our Chief Financial Officer from May 2015 to April 2021. Prior to joining us, Ms. Francis was the Chief Financial Officer for Auxogyn, Inc., a women’s health company, from December 2012 to September 2014. From September 2004 to December 2012, Ms. Francis served as Vice President of Finance, Chief Financial Officer and Treasurer for Promega Corporation, a life science reagent company. From March 2002 to September 2004, Ms. Francis served as the Chief Financial Officer of Bruker BioSciences Corporation, a public life science instrumentation company. From May 2001 to March 2002, Ms. Francis served as Chief Operating Officer and Chief Financial Officer of Nutra-Park Inc., an agricultural biotechnology company. From April 1999 to May 2001, Ms. Francis was Chief Financial Officer of Hypercosm, Inc., a software company. From October 1995 to April 1999, Ms. Francis was an engagement manager with McKinsey & Company, a consulting firm. Early in her career, Ms. Francis was an audit manager with Coopers & Lybrand, an accounting firm. Since January 2019, Ms. Francis has served as a member of the board of directors of ShockWave Medical, Inc, a medical device company. Ms. Francis received a B.B.A. from the University of Wisconsin and an M.B.A. from Stanford University. She is a Certified Public Accountant (inactive) in the State of California. We believe Ms. Francis’s experience in the industry, her role as our Chief Executive Officer, and her knowledge of our company enable her to make valuable contributions to our Board of Directors.
Jeryl L. Hilleman Gregory K. Hinckleyhas served as a member of our Board of Directors since December 2019. Ms. Hilleman brings extensive experienceJanuary 2011. Mr. Hinckley served as President of Mentor Graphics Corporation, an electronic design automation company, from November 2000 until his retirement in life sciencesJuly 2017, and served as a public company CFO for closeon the board of directors from January 1999 to 20 years. Most recently, from June 20142016. From January 1997 to November 2019, Ms. Hilleman2000, he served as Executive Vice President. He has also served as the Chief Financial Officer for Intersect ENT, Inc., a commercial drug delivery company focusing on patients with ear, nose and throat conditions. Prior to Intersect ENT, Ms. Hilleman served as Chief Financial Officer of other public healthcare companies including Ocera Therapeutics, Inc., a biopharmaceutical company; Amyris, Inc., a renewable products company; and Symyx Technologies, a life sciences automation company. Ms. Hilleman has served as a member of the board of directors and the chair of the Audit Committee of NovoCure, Limited and Minerva Neurosciences, Inc. since July 2018, and of Talis Biomedical since March 2021. FromMentor Graphics, first from January 20051997 to July 2016, Ms. Hilleman2007 and again from December 2008 to July 2017. Previously, he served as a member ofon the board of directors of Xenoport,Super Micro Computer, Inc., a biopharmaceuticalmanufacturer of servers, from January 2009 to February 2015; Intermec, Inc., a developer of automated identification and data collection solutions, from July 2004 to September 2013; and Amkor Technology, a semiconductor test and assembly company, from November 1997 to July 2007. From August 1992 to January 1997, Mr. Hinckley served as Senior Vice President, Finance of VLSI Technology, Inc., a designer and manufacturer of custom and semi-custom integrated circuits. From January 1989 to November 1991, he served as Senior Vice President and Chief Financial Officer of Crowley Maritime Corporation, a marine solutions, transportation, and logistics company. Ms. HillemanFrom February 1983 to January 1989, Mr. Hinckley served as Vice President and Chief Financial Officer, and since April 2017, Mr. Hinckley has served on the board of directors of Bio-Rad Laboratories, a manufacturer and supplier of products and systems for the life science research and healthcare markets. Previously, Mr. Hinckley held a number of senior officer positions with Raychem Corporation, a developer of products and services for the aerospace, automotive and telecommunications industries. Mr. Hinckley received a B.A. in HistoryPhysics and Mathematics from BrownClaremont McKenna College and was a Fulbright Scholar in applied mathematics at Nottingham University. He received an M.S. in Applied Physics from the University of California, San Diego and an M.B.A. from the Wharton School at the University of Pennsylvania.Harvard Business School. We believe Ms. Hilleman’sMr. Hinckley’s financial experience, experience with medical devicehis familiarity of serving on the boards of public companies, and herhis knowledge of our company enable herhim to make valuable contributions to our Board of Directors.
THE BOARD OF DIRECTORS RECOMMENDS
A VOTE IN FAVOR OF EACH NAMED NOMINEE
DIRECTORS CONTINUING IN OFFICE UNTIL THE 2023 ANNUAL MEETING
Jeffrey W. Dunn has served as our Executive Chairman since April 2021, as Chairman of our Board of Directors since our inception in April 2008 until April 2021, and as our President and Chief Executive Officer from April 2008 until April 2021. Prior to joining us, Mr. Dunn served as Chief Executive Officer of INBONE Technologies, Inc., an ankle replacement and small bone fusion medical device company, from December 2006 to April 2008, until its sale to Wright Medical Technology, Inc. in April 2008. From August 2000 to June 2006, Mr. Dunn was the Chief Executive Officer of Active Decisions, Inc., a software as a service business, until its sale to Knova Software, Inc. From December 1999 to June 2000, Mr. Dunn was the Chief Executive Officer of Velogic, Inc., an internet performance testing software company, until its sale to Keynote Systems Inc. From June 1999 to December 1999, Mr. Dunn was the Chief Executive Officer of EnterpriseLink Inc., a provider of enterprise Internet enablement software, until its sale to Merant, Inc. From November 1994 to June 1998, Mr. Dunn was Chief Executive Officer of AccelGraphics Inc., a 3D graphics system supplier, until its sale to Evans and Sutherland Computer Corporation. As well, during his career, Mr. Dunn held executive positions with Evans and Sutherland, Cygnet Systems, Inc., Avnet, Inc. and Xerox Corporation. Mr. Dunn received a B.A. from Colgate University and an M.B.A. from Babson College. We believe Mr. Dunn’s experience in the industry, his prior role as our President and Chief Executive Officer, and his knowledge of our company enable him to make valuable contributions to our Board of Directors.
John G. Freund, M.D. has served as a member of our Board of Directors since January 2013. Dr. Freund founded Skyline Ventures, a venture capital firm, in October 1997 and has served as a Managing Director of Skyline since then. In 2016, Dr. Freund co-founded and was CEO of Arixa Pharmaceuticals, Inc. an antibiotic company, which was acquired by Pfizer in 2020. Prior to joining Skyline, Dr. Freund served as Managing Director in the private equity group of Chancellor Capital Management, a private capital investment firm. In November 1995, Dr. Freund co-founded Intuitive Surgical, Inc., a medical device company, and served on its board of directors until March 2000. From 1988 to 1994, he held various positions at Acuson Corporation, a maker of ultrasound equipment that is now part of Siemens, most recently as Executive Vice President. Prior to joining Acuson, Dr. Freund was a general partner of Morgan Stanley Venture Partners from 1987 to 1988. From 1982 to 1988, Dr. Freund was at Morgan Stanley & Co., an investment banking company, where he co-founded the Healthcare Group in the Corporate Finance Department in 1983. Dr. Freund has served on the board of directors of each of Collegium Pharmaceuticals, Inc., a biotechnology company, and Sutro Biopharma, Inc., a biotechnology company, since 2014. Dr. Freund also serves on the board of directors of six U.S. registered investment funds managed by affiliates of the Capital Group, Inc. He also previously served on the board of directors of a number of publicly traded companies, including Tetraphase Pharmaceuticals, Inc., a biopharmaceutical company, Map Pharmaceuticals, Inc., a biopharmaceutical company, MAKO Surgical Corp., a medical device company, Proteon Therapeutics, Inc., a biotechnology company, Concert Pharmaceuticals, Inc., a biopharmaceutical company and was Chairman of XenoPort, Inc., a biopharmaceutical company. Dr. Freund is a member of the Advisory Board for the Harvard Business School Healthcare Initiative. Dr. Freund received a B.A. in History from Harvard College, an M.D. from Harvard Medical School, and an M.B.A. from Harvard Business School, where he was a Baker Scholar. We believe Dr. Freund’s experience with medical device companies, his role in the venture capital industry, and his knowledge of our company enable him to make valuable contributions to our Board of Directors.
Gregory K. Hinckley has served as a member of our Board of Directors since January 2011. Mr. Hinckley served as President of Mentor Graphics Corporation, an electronic design automation company, from November 2000 until his retirement in July 2017, and served on the board of directors from January 1999 to June 2016. From January 1997 to November 2000, he served as Executive Vice President. He has also served as the Chief Financial Officer of Mentor Graphics, first from January 1997 to July 2007 and again from December 2008 to July 2017. Previously, he served on the board of directors of Super Micro Computer, Inc., a manufacturer of servers, from January 2009 to February 2015; Intermec, Inc., a developer of automated identification and data collection solutions, from July 2004 to September 2013; and Amkor Technology, a semiconductor test and assembly company, from November 1997 to July 2007. From August 1992 to January 1997, Mr. Hinckley served as Senior Vice President, Finance of VLSI Technology, Inc., a designer and manufacturer of custom and semi-custom integrated circuits. From January 1989 to November 1991, he served as Senior Vice President and Chief Financial Officer of Crowley Maritime Corporation, a marine solutions, transportation, and logistics company. From February 1983 to January 1989, Mr. Hinckley served as Vice President and Chief Financial Officer, and since April 2017, Mr. Hinckley has served on the board of directors of Bio-Rad Laboratories, a manufacturer and supplier of products and systems for the life science research and healthcare markets. Previously, Mr. Hinckley held a number of senior officer positions with Raychem Corporation, a developer of products and services for the aerospace, automotive and telecommunications industries. Mr. Hinckley received a B.A. in Physics and Mathematics from Claremont McKenna College and was a Fulbright Scholar in applied mathematics at Nottingham University. He received an M.S. in Applied Physics from the University of California, San Diego and an M.B.A. from Harvard Business School. We believe Mr. Hinckley’s financial experience, his familiarity of serving on the boards of public companies, and his knowledge of our company enable him to make valuable contributions to our Board of Directors.
DIRECTORS CONTINUING IN OFFICE UNTIL THE 2024 ANNUAL MEETING
Helen Lohhas served as a member of our Board of Directors since April 2021. Since 2004, Ms. Loh has served as a marketing executive at Charles Schwab, most recently as Managing Director, of Digital, Channels, Education & Client Marketing. From 1999 to 2004, Ms. Loh served as Vice President of Marketing and Product at seeUthere Technologies, an enterprise event management software company. Earlier in her career, Ms. Loh held marketing roles at SINA Corporation, MySoftware Company, and the Clorox Company. Ms. Loh began her career as a management consultant at Marakon, a global strategy consulting firm. Ms. Loh has served on the board of directors of the Charles Schwab Foundation since November 2014. Ms. Loh received a B.S. in Industrial Engineering from Stanford University, and a M.B.A. from Stanford Business School. We believe that Ms. Loh’s experience with digital and consumer marketing will enable her to make valuable contributions to our Board of Directors.
Mika Nishimurahas served as a member of our Board of Directors since March 2021. Since 2011, Ms. Nishimura has served as an Operational Partner with Gilde Healthcare Partners.Partners, a life-science venture fund. Ms. Nishimura ishas served as a board member and the chair of the Nominating and Corporate Governance Committee for Accuray, Inc.,Incorporated, a radiation therapy company since August 2021, and ishas served as a board advisor to Tristel, plc, a UK-based company.company since January 2021. Since June 2022, Ms. Nishimura has served as a member of the board of directors and the Audit, Compensation, Nominating, and Healthcare Compliance Committees of HOYA Corporation. From 2016 to April 2020, Ms. Nishimura was Vice President, Commercialization at nVision Medical Corporation, an early clinical-stage company focused on early detection of ovarian cancer acquired by Boston Scientific. From 2011 to 2015, Ms. Nishimura was Vice President, Commercial Development at Auxogyn, which was acquired by Progyny in 2015. Earlier in her career, Ms. Nishimura was Vice President, International Sales Operations and Marketing at ev3 Inc. Ms. Nishimura has a BA in Economics from Yale University and an MBA from Harvard Graduate School of Business Administration. We believe that Ms. Nishimura’s experience working for medical device companies across multiple phases of commercialization will enable her to make valuable contributions to our Board of Directors.
Keith C. Valentinehas served as a member of our Board of Directors since August 2015. Since July 2015, Mr. Valentine has also servedwas appointed as President, Chief Executive Officer and a member of the board of directors of Orthofix Medical Inc., a medical device company, in January 2023 following its merger with SeaSpine Holdings Corporation, a global medical technology company.company, where Mr. Valentine served as President, Chief Executive Officer and a member of the board since May 2015. From January 2007 to January 2015, he served as President and Chief Operating Officer of NuVasive, Inc., a medical device company. From December 2004 to January 2007, he served as President of NuVasive. From January 2001 to December 2004, he held various senior executive roles in marketing, development and operations at NuVasive. Previously, Mr. Valentine served as Vice President of Marketing at ORATEC Interventions, Inc., a medical device company acquired by Smith & Nephew PLC, and spent eight years in various roles with Medtronic Sofamer Danek including Vice President of Marketing for the Rods Division and Group Director for the BMP Biologics program, Interbody Sales Development, and International Sales and Marketing. Mr. Valentine received a B.B.A. in Management and Biomedical Sciences from Western Michigan University. We believe Mr. Valentine’s experience working forwith medical device companies in the orthopedics and spine surgery fields and his knowledge of our company enable him to make valuable contributions to our Board of Directors.
DIRECTORS CONTINUING IN OFFICE UNTIL THE 2025 ANNUAL MEETING
Timothy E. Davis, Jr. has served as a member of our Board of Directors since our inception in April 2008. Mr. Davis has served as President and Chief Executive Officer of BioTissue Holdings Inc., a privately held company focusing on the development and clinical application of human birth tissue-based products for the ocular and surgical clinical markets, since January 2022. From February 2017 through December 2021, Mr. Davis served as President and Chief Executive Officer of Active Implants, LLC, a company that provides orthopedic implant solutions. From January 2014 through September 2015, Mr. Davis served as Chief Executive Officer of MicroPort Orthopedics, Inc., a multinational producer of orthopedic products, following the purchase of Wright Medical Group’s OrthoRecon Business in January 2014. From December 2006 to January 2014, Mr. Davis served in a number of executive positions for Wright Medical Technology, Inc., a subsidiary of Wright Medical Group, Inc., including President of the OrthoRecon business. From 2004 to 2006, Mr. Davis was a Partner with MB Venture Partners, LLC, a medical technology and life sciences venture capital firm. From 1997 to 2004, Mr. Davis held various positions, ultimately serving as Vice President, with Vector Fund Management, a healthcare and life sciences focused venture capital fund. Early in his career, Mr. Davis worked in the healthcare management consulting and pharmaceutical industries. Mr. Davis received a B.E. degree in Biomedical Engineering from Vanderbilt University and an M.B.A. from the J.L. Kellogg Graduate School of Management at Northwestern University. We believe Mr. Davis’ experience in the industry, his experience in compensation matters, and his knowledge of our company enable him to make valuable contributions to our Board of Directors.
Laura A. Francis has served as our Chief Executive Officer and as a member of our Board of Directors since April 2021. Previously, she served as our Chief Operating Officer from July 2019 to April 2021, and as our Chief Financial Officer from May 2015 to April 2021. Prior to joining us, Ms. Francis was the Chief Financial Officer for Auxogyn, Inc., a women’s health company, from December 2012 to September 2014. From September 2004 to December 2012, Ms. Francis served as Vice President of Finance, Chief Financial Officer and Treasurer for Promega Corporation, a life science reagent company. From March 2002 to September 2004, Ms. Francis served as the Chief Financial Officer of Bruker BioSciences Corporation, a public life science instrumentation company. From May 2001 to March 2002, Ms. Francis served as Chief Operating Officer and Chief Financial Officer of Nutra-Park Inc., an agricultural biotechnology company. From April 1999 to May 2001, Ms. Francis was Chief Financial Officer of Hypercosm, Inc., a software company. From October 1995 to April 1999, Ms. Francis was an engagement manager with McKinsey & Company, a consulting firm. Early in her career, Ms. Francis was an audit manager with Coopers & Lybrand, an accounting firm. Since January 2019, Ms. Francis has served as a member of the board of directors of ShockWave Medical, Inc, a medical device company, including serving as chair of its audit committee and on its compensation committee. Ms. Francis received a B.B.A. from the University of Wisconsin and an M.B.A. from Stanford University. She is a Certified Public Accountant (inactive) in the State of California. We believe Ms. Francis’s experience in the industry, her role as our Chief Executive Officer, and her knowledge of our company enable her to make valuable contributions to our Board of Directors.
Jeryl L. Hilleman has served as a member of our Board of Directors since December 2019. Ms. Hilleman brings extensive experience in life sciences and served as a public company CFO for close to 20 years. Most recently, from June 2014 to November 2019, Ms. Hilleman served as the Chief Financial Officer for Intersect ENT, Inc., a commercial drug delivery company focusing on patients with ear, nose and throat conditions. Prior to Intersect ENT, Ms. Hilleman served as Chief Financial Officer of other public healthcare companies including Ocera Therapeutics, Inc., a biopharmaceutical company; Amyris, Inc., a renewable products company; and Symyx Technologies, a life sciences automation company. Ms. Hilleman has served as a member of the board of directors and the chair of the Audit Committee of NovoCure, Limited and Minerva Neurosciences, Inc. since July 2018, and of Talis Biomedical from July 2018 to June 2022. Ms. Hilleman has served as a member of the board of directors and the Compensation Committee of HilleVax, Inc., a biopharmaceutical company, since April 2021. From January 2005 to July 2016, Ms. Hilleman served as a member of the board of directors of Xenoport, Inc., a biopharmaceutical company. Ms. Hilleman received a B.A. in History from Brown University and an M.B.A. from the Wharton School at the University of Pennsylvania. We believe Ms. Hilleman’s financial experience, experience with medical device companies and her knowledge of our company enable her to make valuable contributions to our Board of Directors.
Each of our directors, other than Mr. Dunn and Ms. Francis, is independent as defined under the Nasdaq Global Market listing standards. See “Independence of the Board of Directors” immediately below.
INFORMATION REGARDING THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE
FAMILY RELATIONSHIPSFamily Relationships
There are no family relationships among the directors and executive officers.
INDEPENDENCE OF THE BOARD OF DIRECTORSIndependence of the Board of Directors
As required under the Nasdaq Global Market (“Nasdaq”) listing standards, a majority of the members of a listed company’s Board of Directors must qualify as “independent,” as affirmatively determined by the Board.Board of Directors. The Board of Directors consults with SI-BONE’s counsel to ensure that the Board’sBoard of Directors’ determinations are consistent with relevant securities and other laws and regulations regarding the definition of “independent,” including those set forth in pertinent listing standards of Nasdaq, as in effect from time to time.
Consistent with these considerations, after review of all relevant identified transactions or relationships between each director, or any of his or her family members, and SI-BONE, its senior management and its independent auditors, the Board of Directors has affirmatively determined that the following seven directors are independent directors within the meaning of the applicable Nasdaq listing standards: Mr. Davis, Dr. Freund, Ms. Hilleman, Mr. Hinckley, Ms. Loh, Ms. Nishimura and Mr. Valentine. In making this determination, the Board of Directors found that none of the directors or nominees for director other than Mr. Dunn and Ms. Francis had a material or other disqualifying relationship with SI-BONE and that each of these directors is “independent” as that term is defined under the rules of the Nasdaq Global Market. Mr. Dunn is not independent given his position as our former President and Chief Executive Officer, and Ms. Francis is not independent given her position as our Chief Executive Officer. The Board made its decision with respect toMr. Valentine after considering that he serves as the President, Chief Executive Officer and a member of the board of directors of SeaSpine Orthopedics Corporation (“SeaSpine”), a company with which we have a joint development agreement, and determined that this relationship would not impair his independence. Accordingly, a majority of our directors are independent, as required under applicable Nasdaq listing rules.
TERM OF SERVICE OF DIRECTORSTerm of Service of Directors
As described in Proposal 1 above, our directors serve for staggered three-year terms. We believe that a classified board, with a supermajority vote of our stockholders required to amend our certificate of incorporation and bylaws and thereby change this structure and/or to take other significant stockholder actions, is in the best long-term interest of our stockholders because it improves board stability and encourages long-term planning. These governance structures are also shared among a majority of our peer companies, including among our compensation peer groups described below. As our company matures, we will continue to evaluate this and other decisions we have made regarding our corporate governance structures. Members of our leadership team hold regular meetings with investors and their governance representatives to discuss their views. While some stockholders have, as a matter of general application, a preference for one-year terms for directors and simple majority voting to amend our certificate of incorporation or bylaws, we have not generally encountered significant or specific objections to the corporate governance decisions we have made.
BOARD SKILLS AND ATTRIBUTESBoard Skills and Attributes
The following matrix provides information regarding the members of our Board of Directors, including certain types of knowledge, skills, experiences and attributes possessed by one or more of our directors which our Board of Directors believes are relevant to our business and industry. The matrix does not encompass all of the knowledge, skills, experiences or attributes of our directors, and the fact that a particular knowledge, skill, experience or attribute is not listed does not mean that a director does not possess it. In addition, the absence of a particular knowledge, skill, experience or attribute with respect to any of our directors does not mean the director in question is unable to contribute to the decision-making process in that area. The type and degree of knowledge, skill and experience listed below may vary among the members of the Board.Board of Directors.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Knowledge, Skills, Experience | | | | | | | |
| Davis | Dunn | Francis | Freund | Hilleman | Hinckley | Loh | Nishimura | Valentine |
| Public Company CEO/Exec Chair (last 5 years) | | • | • | | | | | | • |
| Public Company CFO | | | • | | • | • | | | |
| Senior Executive Leadership | • | • | • | • | • | • | • | • | • |
| Financial Literacy/Expertise | • | • | • | • | • | • | • | • | • |
| Medical Device Industry Experience | • | • | • | • | • | | | • | • |
| Corporate Governance | • | • | • | • | • | • | • | • | • |
| Commercial | • | • | | | | | | • | • |
| Digital Marketing; DTP/DTC Marketing | | | | | | | • | • | • |
| Reimbursement/Payors | • | • | • | | | | | • | • |
| Clinical/Medical | • | • | | • | | | | • | • |
| Regulatory | • | | | | | | | | • |
| R&D | • | | | | | | | | • |
| Business Development/M&A | • | • | • | • | • | • | | • | • |
| Strategic Planning | • | • | • | | • | • | • | • | • |
| Public Relations | | • | | | • | | | | • |
| International | • | • | • | | • | • | | • | • |
| Risk Management | • | | • | | • | | • | • | • |
| Cybersecurity | | | • | | • | | • | | |
| Legal/Compliance/Risk Management | • | • | • | | • | • | • | • | • |
| Human Resources | • | • | • | | • | • | • | • | • |
The following matrix providesmatrices provide race/ethnicity, as well as gender, of the members of our Board of Directors, as self-identified by members of the Board.Board of Directors.
| | | | | | | | |
| Board Diversity Matrix (as of April 14, 2023) |
| Total Number of Directors | 9 | |
| Female | Male |
| Part I: Gender Identity | | |
| Directors | 4 | 5 |
| Part II: Demographic Background | | |
| Asian | 2 | - |
| White | 2 | 5 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Davis | Dunn | Francis | Freund | Hilleman | Hinckley | Loh | Nishimura | Valentine |
| Part I: Demographic Background | | | | | | | | | |
African American or Black | | | | | | | | | |
Alaskan Native or Native American | | | | | | | | | |
| Asian | | | | | | | • | • | |
Hispanic or Latinx | | | | | | | | | |
Indian or South Asian | | | | | | | | | |
Native Hawaiian or Pacific Islander | | | | | | | | | |
Middle Eastern or North African | | | | | | | | | |
| White | • | • | • | • | • | • | | | • |
Two or More Races or Ethnicities | | | | | | | | | |
LGBTQ+ | | | | | | | | | |
Did not Disclose Demographic Background | | | | | | | | | |
| Part II: Gender Identity | | | | | | | | | |
| Male | • | • | | • | | • | | | • |
| Female | | | • | | • | | • | • | |
Non-Binary | | | | | | | | | |
Did Not Disclose Gender | | | | | | | | | |
BOARD LEADERSHIP STRUCTUREBoard Leadership Structure
Our Board of Directors is currently chaired by Mr. Dunn. Mr. Dunn has served as our Executive Chairman since April 2021, when he ceased to serve as our Chief Executive Officer, and Mr. Dunn will continue to serve in such capacity until May 1, 2023, at which time he will become non-executive Chair of the Board. We believe that the separation of the two roles of Executive ChairmanChair of the Board and Chief Executive Officer is most beneficial in furthering SI-BONE’s ability to develop and implement strategy. In particular, in making this determination, Mr. Dunn, as our former Chief Executive Officer, will continue to have intimate knowledge of our operations, both historically and currently, which will enable him to continue to act as a bridge between management and the Board. Further, Mr. Dunn serving as Executive Chairman alleviates the need for Ms. Francis to take on the responsibilities of Chairman,Chairperson, enabling her to focus on her responsibilities in her role as our Chief Executive Officer.In addition, since January 1, 2022, Mr. Davis has resumed his role as our Lead Independent Director.
The Board of Directors believes that our stockholders are best served at this time by having a Lead Independent Director who is an integral part of our Board structure and a critical aspect of effective corporate governance. Mr. Davis previously served asis our Lead
Independent Director from June 2019 untilDirector. Mr. Dunn ceased to be our Chief Executive Officer in April 2021.Mr. Davis brings considerable skills and experience, as described above, to the role. We believe as well that Mr. Davis can effectively oversee and drive the activities of the Board, including:
•coordinatecoordinating with the committee chairs regarding meeting agendas and informational requirements; and
•performperforming such other duties as may be necessary from time to time to ensure the effective functioning of the Board.
ROLE OF THE BOARD IN RISK OVERSIGHTRole of the Board of Directors in Risk Oversight
One of the key functions of our Board of Directors is informed oversight of our risk management process. In particular, our Board is responsible for monitoring and assessing strategic risk exposure. Our executive officers are responsible for the day-to-day management of the material risks we face. Our Board of Directors administers its oversight function directly as a whole, as well as
through various standing committees of our Board of Directors that address risks inherent in their respective areas of oversight. For example, our Audit Committee is responsible for overseeing the management of risks associated with our financial reporting, accounting and auditing matters and cybersecurity; our Compensation Committee oversees the management of risks associated with our compensation policies and programs; and our Nominating and Corporate Governance Committee oversees the management of risks associated with director independence, conflicts of interest, composition and organization of our Board of Directors, director succession planning, development of and reporting on our sustainability program, and oversight of healthcare, regulatory, and fraud and abuse compliance.
Cybersecurity
We recognize the importance of protecting our information technology (“IT”) systems. With this in mind, we focus on IT and cybersecurity measures on both an enterprise-wide operational level and on an individual employee level. Accordingly, we have in place various methods and levels of IT and cybersecurity measures which are aimed at protecting IT systems to help secure long-term value for our shareholders and other stakeholders.
By way of example, these measures generally include the following:
–•Thethe alignment and implementation of formally recognized security frameworks into IT operations and control best practices;
–•Utilizationutilization of detection and protection technologies such as endpoint detection response, vulnerability and patch management programs, and enhanced incident response capabilities;
–•Ongoingongoing end-user security awareness training;
–•Ongoingongoing security metric reporting to senior organizational leaders; and
–•Formalformal periodic risk assessments and maturity assessments to gauge current level of operational efficiency and effectiveness.
Our Audit Committee and senior management are responsible for overseeing matters relating to our IT and cybersecurity practices and initiatives and our Audit Committee is briefed regularlyat least quarterly by our senior management on cybersecurity matters. To further assist our executive team and Audit Committee, we also have designated specific roles to officers and other employees within our company who are responsible for and directly oversee our cybersecurity forefforts. Among the Company.members of our Board, three have served as Chief Financial Officers including direct oversight of Information Technology / Cybersecurity functions, have developed expertise in this area and now serve on the audit committees of other companies' boards with cybersecurity oversight as well. One member of our Board has risk management responsibility in her role as an executive and has obtained certification in cybersecurity oversight from the Software Engineering Institute at Carnegie Mellon University, contributing to her expertise in this area.
MEETINGS OF THE BOARD OF DIRECTORS
Meetings of the Board of Directors
Our Board of Directors met sixfour times during 2021.2022. Each member of the Board memberof Directors attended 75% or more of the aggregate number of meetings of the Board of Directors and of the committees on which he or she served, held during the portion of the last fiscal year for which he or she was a director or committee member.
BOARD COMMITTEES AND MEETINGSBoard Committees and Meetings
Our Board of Directors has three standing committees: an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee. The following table provides membership and meeting information for fiscal 2021year 2022 for each of the Board committees (Mr. Dunn did not serve on any committees in 2021,2022, and neither Mr. Dunn nor Ms. Francis has served on any committee to date):
| | Name | Name | | Audit | | Compensation | | Nominating and Corporate Governance | Name | | Audit | | Compensation | | Nominating and Corporate Governance |
| Timothy E. Davis | Timothy E. Davis | | X | | X* | | | Timothy E. Davis | | X | | X* | | |
John G. Freund, M.D.(1) | John G. Freund, M.D.(1) | | X | | X | John G. Freund, M.D.(1) | | X | |
Jeryl L. Hilleman(2) | Jeryl L. Hilleman(2) | | X* | | X | Jeryl L. Hilleman(2) | | X* | | X |
| Gregory K. Hinckley | Gregory K. Hinckley | | X | | Gregory K. Hinckley | | X | |
Helen Loh(3) | Helen Loh(3) | | X | Helen Loh(3) | | X |
Mika Nishimura(4) | Mika Nishimura(4) | | X | | Mika Nishimura(4) | | X | |
| Keith C. Valentine | Keith C. Valentine | | X* | Keith C. Valentine | | X* |
Mark J. Foley(5) | | X | | |
Karen A Licitra(5) | | X | | |
| | Total meetings in fiscal 2021 | | 8 | | 10 | | 4 | |
| Total meetings in fiscal year 2022 | | Total meetings in fiscal year 2022 | | 5 | | 9 | | 4 |
* Committee Chairperson
(1) Dr. Freund served on the Nominating and Corporate Governance Committee until June 10, 2021, the date of our 2021 annual meeting of stockholders, at which time he left the Nominating and Corporate Governance Committee and joined the Compensation Committee.
(2) Ms. Hilleman joined the Nominating and Corporate Governance Committee on June 10, 2021.
(3) Ms. Loh joined our Board in April 2021 and joined the Nominating and Corporate Governance Committee on June 10, 2021.
(4) Ms. Nishimura joined our Board in March 2021 and joined the Compensation Committee on June 10, 2021.
(5) Mr. Foley and Ms. Licitra ceased to be a member of our Board and the Compensation Committee on June 10, 2021.
Our Board of Directors has adopted a written charter for each of the Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee. Each of these charters are available to stockholders on SI-BONE’s website at www.si-bone.com.
Below is a description of each committee of the Board.Board of Directors.
Audit Committee
Our Audit Committee consists of Mr. Davis, Mr. Hinckley, and Ms. Hilleman, each of whom satisfies the independence requirements under the Nasdaq Global Market listing standards and Rule 10A-3(b)(1) of the Exchange Act. The chairperson of our Audit Committee is Ms. Hilleman. Our Board has determined that each of Mr. Davis, Mr. Hinckley, and Ms. Hilleman are “audit committee financial experts” within the meaning of SEC regulations. Our Board has also determined that each member of our Audit Committee has the requisite financial expertise required under the applicable requirements of the Nasdaq Global Market. In arriving at this determination, the Board has examined each audit committee member’s scope of experience and the nature of their employment in the corporate finance sector.
The primary purpose of the Audit Committee is to discharge the responsibilities of our Board with respect to our accounting, financial, and other reporting and internal control practices and to oversee our independent registered public accounting firm. Specific responsibilities of our Audit Committee include, but are not limited to:
•selecting a qualified firm to serve as the independent registered public accounting firm to audit our financial statements;
•evaluating the qualifications, independence and performance of the independent registered public accounting firm;
•determining the scope of the annual audit and the audit fee;
•reviewing our financial statements and our management’s discussion and analysis of financial condition and results of operations to be included in our annual and quarterly reports to be filed with the SEC;
•considering the adequacy of our internal controls;
•developing and overseeing procedures for employees to submit concerns anonymously about questionable accounting or audit matters;
•reviewing related party transactions;
•reviewing and discussing the adequacy and effectiveness of our accounting and financial reporting processes and internal controls and the annual audits of our financial statements;
•approving (or, as permitted, pre-approving) all audit and all permissible non-audit service to be performed by the independent registered public accounting firm;
•reviewing our guidelines and policies with respect to financial and information security risk management; and
•reviewing, at least annually, the Audit Committee charter and the committee’s performance.
Our Board reviews the Nasdaq listing standards definition of independence for Audit Committee members on an annual basis and has determined that all members of SI-BONE’s Audit Committee are independent (as independence is currently defined in Rule 5605(c)(2)(A)(i) and (ii) of the Nasdaq listing standards).
Report of the Audit Committee of the Board of Directors
Our Audit Committee has reviewed and discussed the audited financial statements for the fiscal year ended December 31, 20212022 with management of SI-BONE. The Audit Committee has discussed with the independent registered public accounting firm the matters required to be discussed by the applicable requirements of the Public Company Accounting Oversight Board (“PCAOB”) and the Securities and Exchange Commission. The Audit Committee has also received the written disclosures and the letter from the independent registered public accounting firm required by applicable requirements of the PCAOB regarding the independent accountants’ communications with the audit committee concerning independence and has discussed with the independent registered public accounting firm the accounting firm’s independence. Based on the foregoing, the Audit Committee has recommended to the Board of Directors that the audited financial statements be included in SI-BONE’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021.2022.
Jeryl L. Hilleman (Chairperson)
Gregory K. Hinckley
Timothy E. Davis
The material in this report is not “soliciting material,” is not deemed “filed” with the Commission and is not to be incorporated by reference in any filing of SI-BONE under the Securities Act or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.
Compensation Committee
Our Compensation Committee consists of Mr. Davis, Dr. Freund and Ms. Nishimura, each of whom our Board has determined to be independent under the Nasdaq Global Market listing standards, and a “non-employee director” as defined in Rule 16b-3 promulgated under the Exchange Act. The chairperson of our Compensation Committee is Mr. Davis.
The primary purpose of our Compensation Committee is to discharge the responsibilities of our Board to oversee our compensation policies, plans, and programs and to review and determine the compensation to be paid to our executive officers, directors, and other senior management, as appropriate. Specific responsibilities of our Compensation Committee include:
•reviewing and approving, or in the case of our Chief Executive Officer, recommending that our Board approve, the compensation of our executive officers;
•reviewing and recommending to our Board the compensation of our directors;
•reviewing and approving, or recommending that our Board approve, the terms of compensatory arrangements with our executive officers;
•administering our employee stock purchase and equity incentive plans;
•selecting independent compensation consultants and assessing whether there are any conflicts of interest with any of the committee’s compensation advisors;
•reviewing and approving, or recommending that our Board approve, incentive compensation and equity plans, severance agreements, change-of-control protections, and any other compensatory arrangements for our executive officers and other senior management, as appropriate;
•reviewing and establishing general policies relating to compensation and benefits of our employees; and
•reviewing our overall compensation philosophy.
Compensation Committee Processes and Procedures
Typically, our Compensation Committee meets at least four times annually and with greater frequency if necessary. The agenda for each meeting is usually developed by the chair of the Compensation Committee, in consultation with the Chief Legal Officer.General Counsel. The Compensation Committee meets regularly in executive session. However, from time to time, various members of management and other employees as well as outside advisors or consultants may be invited by the Compensation Committee to make presentations, to provide financial or other background information or advice or to otherwise participate in Compensation Committee meetings. The Chief Executive Officer may not participate in, or be present during, any deliberations or determinations of the Compensation Committee regarding his or her compensation or individual performance objectives. The charter of the Compensation Committee grants the Compensation Committee full access to all books, records, facilities and personnel of SI-BONE. In addition, under the charter, the Compensation Committee has the authority to obtain, at the expense of SI-BONE, advice and assistance from compensation consultants and internal and external legal, accounting or other advisors and other external resources that the Compensation Committee considers necessary or appropriate in the performance of its duties. The Compensation Committee has direct responsibility for the oversight of the work of any consultants or advisers engaged for the purpose of advising the Committee. In particular, the Compensation Committee has the sole authority to retain, in its sole discretion, compensation consultants to assist in its evaluation of executive and director compensation, including the authority to approve the consultant’s reasonable fees and other retention terms. Under the charter, the Compensation Committee may select, or receive advice from, a compensation consultant, legal counsel or other adviser to the Compensation Committee, other than in-house legal counsel and certain other types of advisers, only after taking into consideration six factors, prescribed by the SEC and Nasdaq, that bear upon the adviser’s independence; however, there is no requirement that any adviser be independent.
During the past fiscal year, after taking into consideration the six factors prescribed by the SEC and Nasdaq described above, the Compensation Committee engaged Compensia, Inc., a national compensation consulting firm with compensation expertise relating to technology and life science companies, as compensation consultants. The Compensation Committee requested that Compensia:
•evaluate the efficacy of SI-BONE’s existing compensation strategy and practices in supporting and reinforcing SI-BONE’s long-term strategic goals;
•assist in refining SI-BONE’s compensation strategy and in developing and implementing an executive compensation program to execute that strategy;
•benchmark SI-BONE’s use of its equity in its compensation program against equity utilization of its peers;
•review the adequacy and appropriateness of SI-BONE’s compensation of its independent directors and recommend annuallyannual updates to the Company’s non-employee director compensation policy; and
•perform an annual independent compensation risk assessment.
As part of its engagement, the Compensation Committee requested Compensia to develop a comparative group of companies and to perform analyses of competitive performance and compensation levels for that group. Compensia also conducted individual interviews with members of the Compensation Committee and senior management to learn more about SI-BONE’s business operations and strategy, key performance metrics and strategic goals, as well as the labor markets in which SI-BONE competes. Compensia ultimately developed recommendations that were presented to the Compensation Committee for its consideration. Following an active dialogue with Compensia, the Compensation Committee approved the recommendations of Compensia.
Historically, the Compensation Committee has made most of the significant adjustments to annual compensation, determined bonus and equity awards and established new performance objectives at one or more meetings held during the fourth quarter of the preceding year and the first quarter of the year. However, the Compensation Committee also considers matters related to individual compensation, such as compensation for new executive hires, as well as high-level strategic issues, such as the efficacy of SI-BONE’s compensation strategy, potential modifications to that strategy and new trends, plans or approaches to compensation, at various meetings throughout the year. Generally, the Compensation Committee’s process comprises two related elements: the determination of compensation levels and the establishment of performance objectives for the current year. For executives other than the Chief Executive Officer, the Compensation Committee solicits and considers evaluations and recommendations submitted to the Committee by the Chief Executive Officer. In the case of the Chief Executive Officer, the Board conducts the evaluation of his or her performance, which determines any adjustments to his or her compensation as well as awards to be granted. For all executives and directors as part of its deliberations, the Compensation Committee may review and consider, as appropriate, materials such as financial reports and projections, operational data, tax and accounting information, tally sheets that set forth the total compensation that may become payable to executives in various hypothetical scenarios, executive and director stock ownership information, company stock performance data, analyses of historical executive compensation levels and current Company-wide compensation levels and recommendations of the Compensation Committee’s compensation consultant, including analyses of executive and director compensation paid at other companies identified by the consultant.
Nominating and Corporate Governance Committee
Our Nominating and Corporate Governance Committee consists of Ms. Hilleman, Ms. Loh and Mr. Valentine. Our Board of Directors has determined Ms. Hilleman, Ms. Loh and Mr. Valentine each to be independent under the Nasdaq Global Market listing standards. The chairperson of our Nominating and Corporate Governance Committee is Mr. Valentine.
Specific responsibilities of our Nominating and Corporate Governance Committee include:
•identifying, evaluating, and selecting, or recommending that our Board approve, nominees for election to our Board;
•overseeing the process of evaluating the performance of our Board of Directors;
•reviewing developments in corporate governance practices;
•evaluating the adequacy of our corporate governance practices and reporting;
•reviewing management succession plans;
•developing and making recommendations to our Board regarding corporate governance guidelines and matters;
•overseeing management of our environmental, social and governance oversight program; and
•overseeing administration of our healthcare compliance program.
The Nominating and Corporate Governance Committee believes that candidates for director should have certain minimum qualifications, including the ability to read and understand basic financial statements, being over 21 years of age and having the highest personal integrity and ethics. The Nominating and Corporate Governance Committee also intends to consider such factors as
possessing relevant expertise upon which to be able to offer advice and guidance to management, having sufficient time to devote to the affairs of SI-BONE, demonstrated excellence in his or her field, having the ability to exercise sound business judgment and having
the commitment to rigorously represent the long-term interests of SI-BONE’s stockholders. However, the Nominating and Corporate Governance Committee retains the right to modify these qualifications from time to time. Potential director nominees are reviewed in the context of the current composition of the Board, the operating requirements of SI-BONE and the long-term interests of its stockholders. In conducting this assessment, the Nominating and Corporate Governance Committee considers diversity (including gender, racial and ethnic diversity), age, skills and such other factors as it deems appropriate, given the current needs of the Board and SI-BONE, to maintain a balance of knowledge, experience and capability.
The Nominating and Corporate Governance Committee appreciates the value of thoughtful Board refreshment, and regularly identifies and considers qualities, skills and other director attributes that would enhance the composition of the Board. In the case of incumbent directors whose terms of office are set to expire, the Committee reviews these directors’ overall service to SI-BONE during their terms, including the number of meetings attended, level of participation, quality of performance and any other relationships and transactions that might impair the directors’ independence. In the case of potential director nominees, the Nominating and Corporate Governance Committee also determines whether the candidate is independent for Nasdaq purposes, which determination is based upon applicable Nasdaq listing standards, applicable SEC rules and regulations and the advice of counsel, if necessary. The Nominating and Corporate Governance Committee then uses its network of contacts to compile a list of potential nominees, but may also engage, if it deems appropriate, a professional search firm. The Nominating and Corporate Governance Committee conducts any appropriate and necessary inquiries into the backgrounds and qualifications of possible candidates after considering the function and needs of the Board. The Nominating and Corporate Governance Committee meets to discuss and consider the candidates’ qualifications and then selects a nominee for recommendation to the Board by majority vote.
The Nominating and Corporate Governance Committee will consider director candidates recommended by stockholders. The Nominating and Corporate Governance Committee does not intend to alter the manner in which it evaluates candidates, including the minimum criteria set forth above, based on whether or not the candidate was recommended by a stockholder. Stockholders who wish to recommend individuals for consideration by the Nominating and Corporate Governance Committee to become nominees for election to the Board may do so by delivering a written recommendation to the attention of the Nominating and Corporate Governance Committee and care of the Chief Legal OfficerGeneral Counsel at the following address: 471 El Camino Real, Suite 101, Santa Clara, CACalifornia 95050 no earlier than 120 days prior to the anniversary date of the mailing of SI-BONE’s proxy statement for the last Annual Meeting of Stockholders and no later than the 90th day prior to the upcoming annual meeting. Submissions must include the full name of the proposed nominee, a description of the proposed nominee’s business experience for at least the previous five years, complete biographical information, a description of the proposed nominee’s qualifications as a director and a representation that the nominating stockholder is a beneficial or record holder of SI-BONE’s stock and has been a holder for at least one year. Any such submission must be accompanied by the written consent of the proposed nominee to be named as a nominee and to serve as a director if elected.
STOCKHOLDER COMMUNICATIONS WITH THE BOARD OF DIRECTORSStockholder Communications with the Board of Directors
Historically, we have not provided a formal process related to stockholder communications with our Board of Directors. Nevertheless, every effort has been made to ensure that the views of stockholders are heard by the Board or individual directors, as applicable, and that appropriate responses are provided to stockholders in a timely manner. We believe our responsiveness to stockholder communications to our directors has been excellent. Stockholders may communicate with the Board or any of our directors. Stockholders who wish to communicate with the Board may do so by sending written communications addressed as follows: SI-BONE, Inc. Board Communication, 471 El Camino Real, Suite 101, Santa Clara, CACalifornia 95050. Any communication sent must state the number of shares owned by the stockholder making the communication. The communications will be reviewed by the Chairman of the Board. The Chairman of the Board will forward such communication to the Board or to any individual director to whom the communication is addressed unless the communication is unduly frivolous, hostile, threatening or similarly inappropriate, in which case, the Chairman of the Board shall discard the communication.
CODE OF BUSINESS CONDUCT AND ETHICSCode of Business Conduct and Ethics
We have adopted the SI-BONE, Inc. Code of Business Conduct and Ethics that applies to all officers, directors and employees. The Code of Business Conduct and Ethics is available on SI-BONE’s website at www.si-bone.com. If SI-BONE makes any substantive amendments to the Code of Business Conduct and Ethics or grants any waiver from a provision of the Code to any executive officer or director, SI-BONE will promptly disclose the nature of the amendment or waiver on its website.
We have a whistleblower hotline and website where people can report violations of the Code of Business Conduct and Ethics anonymously or by name; to date we have never had a good-faith complaint alleging violations of our Code of Conduct come into the hotline.
CORPORATE GOVERNANCE GUIDELINES
Corporate Governance Guidelines
In July 2018, the Board of Directors adopted, and in January 2021 and December 2022 revised, our Corporate Governance Guidelines to assure that the Board has the necessary authority and policies in place to review and evaluate SI-BONE’s business operations as needed and to make decisions that are independent of SI-BONE’s management. The guidelines are also intended to align the interests of directors and management with those of SI-BONE’s stockholders. The Corporate Governance Guidelines set forth the practices the Board intends to follow with respect to board composition and selection including diversity, board meetings and involvement of senior management, Chief Executive Officer performance evaluation and succession planning, board committees and compensation, board and committee self-assessments, and our prohibition on engaging in hedging, pledging or other inherently speculative transactions in our common stock. The Corporate Governance Guidelines, as well as the charters for each committee of the Board, may be viewed at www.si-bone.com.
HEDGING AND PLEDGING PROHIBITIONHedging and Pledging Prohibition
As set forth in our Insider Trading Policy and Corporate Governance Guidelines, no director, employee or consultant to SI-BONE may engage in short sales, transactions in put or call options, hedging transactions, margin accounts, pledges, or other inherently speculative transactions with respect to our stock at any time.
STOCK OWNERSHIP GUIDELINESStock Ownership Guidelines
In December 2020, the Board of Directors adopted stock ownership guidelines applicable to each of our directors and executive officers. Pursuant to these guidelines, our Chief Executive Officer is expected to own shares of our common stock with a value of at least three times his or her annual base pay, each of our executive officers other than our Chief Executive Officer is expected to own shares of our common stock with a value of at least his or her annual base salary, and each of our directors is expected to own shares of our common stock with a value of at least three times our annual retainer for independent directors for service on the Board of Directors. The guidelines provide that the applicable person has five years from the later of the adoption of this policy and the time the person becomes subject to this policy to achieve their applicable stock ownership.
ENVIRONMENTAL, SOCIAL, AND GOVERNANCEEnvironmental, Social, and Governance (ESG) OVERSIGHT AND ACTIVITIESOversight and Activities
We strive to advance the interests of all our stakeholders – including patients, healthcare professionals, employees, investors, and our communities – by operating in an ethical and sustainable way. We do this by holding true to our core values: Respect, Collaboration, Excellence, Creativity, Agility and Integrity. These values are at the heart of our sustainability activities. For more information about our sustainability achievements in 2021,2022, we encourage you to read our 20212022 Sustainability Report, which will beis available for download at www.investor.si-bone.comwww.investor.si-bone.com/sustainability in May 2022.April 2023. This report and any content on our website is provided for reference only and is not incorporated by reference in this Proxy Statement.
PROPOSAL NO. 2
RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Audit Committee of the Board of Directors has selected PricewaterhouseCoopers LLP as SI-BONE’s independent registered public accounting firm for the fiscal year ending December 31, 2022,2023, and has further directed that management submit the selection of its independent registered public accounting firm for ratification by the stockholders at the annual meeting.Annual Meeting. PricewaterhouseCoopers LLP has audited SI-BONE’s financial statements since our inception in 2008. Representatives of PricewaterhouseCoopers LLP are expected to be present at the Annual Meeting. They will have an opportunity to make a statement if they so desire and will be available to respond to appropriate questions.
Neither our Bylaws or other governing documents nor law require stockholder ratification of the selection of PricewaterhouseCoopers LLP as SI-BONE’s independent registered public accounting firm. However, the Audit Committee of the Board is submitting the selection of PricewaterhouseCoopers LLP to the stockholders for ratification as a matter of good corporate practice. If the stockholders fail to ratify the selection, the Audit Committee of the Board will reconsider whether or not to retain that firm. Even if the selection is ratified, the Audit Committee of the Board in its discretion may direct the appointment of different independent auditors at any time during the year if they determine that such a change would be in the best interests of SI-BONE and its stockholders.
The affirmative vote of the holders of a majority of the shares present in person or represented by proxy and entitled to vote on the matter at the annual meetingAnnual Meeting will be required to ratify the selection of PricewaterhouseCoopers LLP.
PRINCIPAL ACCOUNTANT FEES AND SERVICESPrincipal Accountant Fees and Services
The following table represents aggregate fees billed to SI-BONE for the fiscal years endedending December 31, 2022 and 2021, and 2020respectively, by PricewaterhouseCoopers LLP, our independent registered public accounting firm.
| | | Fiscal Year Ended | | Fiscal Year Ended |
| | 2021 | | 2020 | | 2022 | | 2021 |
| | (in thousands) | | (in thousands) |
| Audit Fees | Audit Fees | $ | 1,520 | | $ | 1,039 | Audit Fees | $ | 1,203 | | $ | 1,520 |
| Audit-related Fees | Audit-related Fees | — | | — | Audit-related Fees | — | | — |
| Tax Fees | Tax Fees | 92 | | 111 | Tax Fees | 67 | | 92 |
| All Other Fees | All Other Fees | 1 | | 1 | All Other Fees | 1 | | 1 |
| Total Fees | Total Fees | $ | 1,613 | | $ | 1,151 | Total Fees | $ | 1,271 | | $ | 1,613 |
•Audit Fees consist of fees incurred for professional services rendered for the audit of our annual consolidated financial statements, review of our quarterly consolidated financial statements, and other services normally provided by PricewaterhouseCoopers LLP in connection with regulatory filings.
•Tax Fees consist of fees for professional services for tax compliance, tax advice and tax planning.
•All Other Fees consist of fees for professional services other than the services reported above, including permissible consulting services.
All fees described above were pre-approved by the Audit Committee.
PRE-APPROVAL POLICIES AND PROCEDURES.Pre-Approval Policies and Procedures
Our Audit Committee has adopted a policy and procedures for the pre-approval of audit and non-audit services rendered by SI-BONE’s independent registered public accounting firm, PricewaterhouseCoopers LLP. The policy generally pre-approves specified services in the defined categories of audit services, audit-related services and tax services up to specified amounts. We also maintain a small standing authority for management to direct pre-approved fees, the uses of which are reviewed by the Audit Committee and the pre-approved amount of which is replenished as necessary at each meeting. Pre-approval may also be given as part of the Audit Committee’s approval of the scope of the engagement of the independent auditor or on an individual, explicit, case-by-case basis before the independent auditor is engaged to provide each service. The pre-approval of services may be delegated to one or more of the Audit Committee’s members, but the decision must be reported to the full Audit Committee at its next scheduled meeting.
The Audit Committee has determined that the rendering of services other than audit services by PricewaterhouseCoopers LLP is compatible with maintaining the principal accountant’s independence.
THE BOARD OF DIRECTORS RECOMMENDS
A VOTE IN FAVOR OF PROPOSAL NO. 2.
PROPOSAL NO. 3
ADVISORY VOTE ON EXECUTIVE COMPENSATION
Under the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, and Section 14A of the Exchange Act, our stockholders are entitled to vote to approve, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement in accordance with SEC rules.
This vote is not intended to address any specific item of compensation, but rather the overall compensation of our named executive officers and the philosophy, policies and practices described in this proxy statement. The compensation of our named executive officers subject to the vote is disclosed in the compensation tables and the related narrative disclosure contained in this proxy statement. As discussed in those disclosures, we believe that our compensation policies and decisions are focused on pay-for-performance principles and strongly aligned with our stockholders’ interests, consistent with current market practices. Compensation of our named executive officers is designed to enable us to attract and retain talented and experienced executives to lead our company successfully in a competitive environment. Please see the Executive Compensation Narrative for a description of our compensation policies and decisions.
Accordingly, the Board is asking our stockholders to indicate their support for the compensation of our named executive officers as described in this proxy statement by casting a non-binding advisory vote “FOR” the following resolution:
“RESOLVED, that the compensation paid to our named executive officers, as disclosed pursuant to Item 402 of Regulation S-K, including the compensation tables and narrative discussion, is hereby APPROVED.”
Because the vote is advisory, it is not binding on the Board of Directors or SI-BONE. Nevertheless, the views expressed by our stockholders, whether through this vote or otherwise, are important to management and the Board and, accordingly, the Board and the Compensation Committee intend to consider the results of this vote in making determinations in the future regarding executive compensation arrangements.
Advisory approval of this proposal requires the vote of the holders of a majority of the shares present via webcast or represented by proxy and entitled to vote on the matter at the annual meeting.Annual Meeting. Unless the Board decides to modify its policy regarding the frequency of soliciting advisory votes on the compensation of our named executives, the next scheduled say-on-pay vote will be at the 20232024 Annual Meeting of Stockholders.
THE BOARD OF DIRECTORS RECOMMENDS
A VOTE IN FAVOR OF PROPOSAL NO. 3
PROPOSAL NO. 4
ADVISORY VOTE ON THE FREQUENCY OF STOCKHOLDER
ADVISORY VOTES ONEXECUTIVE COMPENSATION
The Dodd-Frank Wall Street Reform and Consumer Protection Act, and Section 14A of the Exchange Act, enable our stockholders, at least once every six years, to indicate their preference regarding how frequently we should solicit a non-binding advisory vote on the compensation of our named executive officers as disclosed in our proxy statement. In accordance with the Dodd-Frank Act, we are asking our stockholders to indicate whether they would prefer an advisory vote every year, every other year or every three years. Alternatively, our stockholders may abstain from casting a vote.For the reasons described below, the Board recommends that stockholders select a frequency of one year.
The Board believes that an annual advisory vote on the compensation of our named executive officers will enable our stockholders to collectively express their level of approval of our executive compensation program each year, thereby enabling us to be more responsive to the views of our stockholders as both our compensation program and stockholder base evolve over time.In formulating its recommendation, the Board considered that an annual advisory vote on executive compensation will allow stockholders to provide direct and timely input on our compensation philosophy, policies and practices. Additionally, an annual advisory vote on executive compensation is consistent with our policy of seeking input from, and engaging in discussions with, our stockholders on executive compensation and corporate governance matters.
However, the Board encourages our stockholders to express their preference in accordance with what they determine to be best for SI-BONE.Accordingly, the Board is asking our stockholders to indicate their preferred voting frequency by voting for one, two or three years or abstaining from voting on this proposal.The alternative among one year, two years or three years that receives the votes of the holders of a majority of shares present via webcast or represented by proxy and entitled to vote on the matter at the annual meeting will be deemed to be the frequency preferred by the stockholders and will be the alternative selected in the following resolution to be submitted to the stockholders for a vote at the annual meeting:
“RESOLVED, that the frequency of every [one year][two years][three years] is hereby APPROVED as the frequency preferred by stockholders for the solicitation of advisory stockholder approval of the compensation paid to the company’s NEOs.” While the Board believes that its recommendation is appropriate at this time, the stockholders are not voting to approve or disapprove that recommendation, but are instead asked to indicate their preferences, on an advisory basis, as to whether the non-binding advisory vote on the approval of our executive officer compensation practices should be held every year, every other year or every three years.If no frequency receives votes representing a majority of shares held by stockholders present via webcast or represented by proxy and entitled to vote at the meeting, the option among those choices that receives the highest number of votes from the holders of shares present via webcast or represented by proxy and entitled to vote at the annual meeting will be deemed to be the frequency preferred by the stockholders.
The Board and the Compensation Committee value the opinions of our stockholders in this matter and, to the extent there is any significant vote in favor of one frequency over the other options, even if less than a majority, the Board will consider the stockholders’ concerns and evaluate any appropriate next steps.However, because this vote is advisory and, therefore, not binding on the Board of Directors or SI-BONE, the Board may decide that it is in the best interests of the stockholders that we hold an advisory vote on executive compensation more or less frequently than the option preferred by the stockholders. The vote will not be construed to create or imply any change or addition to the fiduciary duties of SI-BONE or the Board.
THE BOARD OF DIRECTORS RECOMMENDS
A VOTE IN FAVOR OF “ONE YEAR” ON PROPOSAL NO. 4.
SECURITY OWNERSHIP OF
CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth certain information regarding the ownership of SI-BONE’s common stock as of March 31, 2022,2023, by: (i) each director and nominee for director; (ii) each of the executive officers named in the Summary Compensation Table; (iii) all executive officers and directors of SI-BONE as a group; and (iv) all those known by SI-BONE to be beneficial owners of more than five percent of its common stock.
This table is based upon information supplied by officers, directors and principal stockholders and Schedules 13G filed with the SEC. Unless otherwise indicated in the footnotes to this table and subject to community property laws where applicable, SI-BONE believes that each of the stockholders named in this table has sole voting and investment power with respect to the shares indicated as beneficially owned. Applicable percentages are based on 33,872,36335,106,163 shares outstanding on March 31, 2022,2023, adjusted as required by rules promulgated by the SEC.
| | | Total Beneficial Ownership | | Total Beneficial Ownership |
| Name of Beneficial Owner | Name of Beneficial Owner | Shares Owned | Right to Acquire Shares Within 60 days | Number of Shares | Percent of Total | Name of Beneficial Owner | Shares Owned | Right to Acquire Shares Within 60 days | Number of Shares Beneficially Owned | Percent of Total |
| Named Executive Officers and Directors: | Named Executive Officers and Directors: | | Named Executive Officers and Directors: | |
| Timothy E. Davis, Jr. | Timothy E. Davis, Jr. | 15,223 | | 71,138 | | 86,361 | | * | Timothy E. Davis, Jr. | 19,071 | | 71,138 | | 90,209 | | * |
Jeffrey W. Dunn(1) | Jeffrey W. Dunn(1) | 84,975 | | 683,463 | | 768,438 | | 2.2 | % | Jeffrey W. Dunn(1) | 132,882 | | 703,790 | | 836,672 | | 2.3 | % |
John G. Freund, M.D.(2) | John G. Freund, M.D.(2) | 142,696 | | 37,963 | | 180,659 | | * | John G. Freund, M.D.(2) | 146,544 | | 37,963 | | 184,507 | | * |
| Jeryl L. Hilleman | Jeryl L. Hilleman | 4,397 | | 21,135 | | 25,532 | | * | Jeryl L. Hilleman | 6,321 | | 26,236 | | 32,557 | | * |
Gregory K. Hinckley(3) | Gregory K. Hinckley(3) | 143,149 | | 18,826 | | 161,975 | | * | Gregory K. Hinckley(3) | 146,997 | | 18,826 | | 165,823 | | * |
| Helen Loh | Helen Loh | 2,287 | | 685 | | 2,972 | | * | Helen Loh | 5,025 | | 684 | | 5,709 | | * |
| Mika Nishimura | Mika Nishimura | 2,500 | | — | | 2,500 | | * | Mika Nishimura | 5,922 | | — | | 5,922 | | * |
| Keith C. Valentine | Keith C. Valentine | 40,171 | | 37,963 | | 78,134 | | * | Keith C. Valentine | 44,019 | | 37,963 | | 81,982 | | * |
| Laura A. Francis | Laura A. Francis | 101,664 | | 129,528 | | 231,192 | | * | Laura A. Francis | 164,740 | | 92,388 | | 257,128 | | * |
| Anshul Maheshwari | Anshul Maheshwari | — | | 12,173 | | 12,173 | | * | Anshul Maheshwari | 22,138 | | 8,594 | | 30,732 | | * |
| Anthony J. Recupero | Anthony J. Recupero | 34,885 | | 201,402 | | 236,287 | | * | Anthony J. Recupero | 58,297 | | 210,879 | | 269,176 | | * |
All executive officers and directors as a group (12 persons)(4) | 608,851 | | 1,281,908 | | 1,890,759 | | 5.4 | % | |
| All executive officers and directors as a group (11 persons) | | All executive officers and directors as a group (11 persons) | 751,956 | | 1,208,461 | | 1,960,417 | | 5.4 | % |
| | 5% Stockholders: | 5% Stockholders: | | 5% Stockholders: | |
Brown Advisory Incorporated(5)(4) | Brown Advisory Incorporated(5)(4) | 3,177,024 | | — | | 3,177,024 | | 9.4 | % | Brown Advisory Incorporated(5)(4) | 3,849,827 | | — | | 3,849,827 | | 11.0 | % |
OrbiMed Capital LLC(5) | | OrbiMed Capital LLC(5) | 3,201,100 | | — | | 3,201,100 | | 9.1 | % |
Blackrock, Inc.(6) | Blackrock, Inc.(6) | 2,699,798 | | — | | 2,699,798 | | 8.0 | % | Blackrock, Inc.(6) | 2,821,847 | | — | | 2,821,847 | | 8.0 | % |
OrbiMed Capital LLC(7) | 2,305,300 | | — | | 2,305,300 | | 6.8 | % | |
First Light Asset Management, LLC(7) | | First Light Asset Management, LLC(7) | 2,104,337 | | — | | 2,104,337 | | 6.0 | % |
Champlain Investment Partners, LLC(8) | Champlain Investment Partners, LLC(8) | 1,970,385 | | — | | 1,970,385 | | 5.8 | % | Champlain Investment Partners, LLC(8) | 1,743,355 | | — | | 1,743,355 | | 5.0 | % |
|
* Less than one percent.
(1) The outstanding shares consist of 84,975(i) 111,673 shares of common stock held by Jeffrey W. Dunn as Trustee of the Jeffrey W. Dunn Living Trust Dated May 17, 2012.2012 and (ii) 21,209 shares held by Mr. Dunn.
(2) The outstanding shares include (i) 133,899 shares of common stock held by the John Freund Family Partnership IV, L.P. and (ii) 8,79712,645 shares held by Dr. Freud.Freund.
(3) The outstanding shares consist of (i) 67,54671,394 shares of common stock held by Mr. Hinckley and (ii) 75,603 shares of common stock held by Gregory K. Hinckley and Mary C. Hinckley as Community Property with the Right of Survivorship.
(4) Consists of (i) 571,947 shares of outstanding common stock beneficially owned by our directors and Named Executive Officers as listed in the table and 36,904 shares of outstanding common stock beneficially owned by our other executive officer as of
March 31, 2022 not listed in the table, and (ii) the right to acquire 1,214,276 shares of common stock within 60 days of March 31, 2022 by our directors and Named Executive Officers listed in the table and by our other executive officer; the number of shares our other executive officer has the right to acquire is 67,632 shares of common stock.
(5) Based on a Schedule 13G filed on February 7, 2022,9, 2023, reporting beneficial ownership as of December 31, 2021.2022. Brown Advisory Incorporated has sole voting power over 2,736,9233,330,031 of these shares and shared dispositive power over all of these shares. Brown Advisory LLC has sole voting power over 2,720,499 of these shares and shared dispositive power over 3,160,600 of these shares. Brown Investment Advisory & Trust Company has sole voting power and shared dispositive power over 16,42421,392 of these shares.The address for Brown Advisory Incorporated is 901 SSouth Bond Street, Suite 400, Baltimore, MDMaryland 21231.
(5) Based on a Schedule 13G/A filed on February 14, 2023, reporting beneficial ownership as of December 31, 2022. OrbiMed Capital LLC has sole voting power and sole dispositive power over all of these shares. Orbimed Advisors LLC has shares voting and dispositive power over 166,900 of these shares. The address for OrbiMed Capital LLC and Orbimed Advisors LLC is 601 Lexington Avenue, 54th Floor, New York, New York 10022.
(6) Based on a Schedule 13G/A filed February 3, 2022,2023, reporting beneficial ownership as of December 31, 2021.2022. Blackrock, Inc. has sole voting power over 2,666,2582,780,778 of these shares and sole dispositive power over all of these2,821,847 shares. The address for Blackrock, Inc. is 55 East 52nd Street, New York, New York 10055.
(7) Based on a Schedule 13G filed on February 11, 2022,14, 2023, reporting beneficial ownership as of December 31, 2021. OrbiMed Capital2022. Each of First Light Asset Management, LLC (“First Light”) and Mathew P. Arens has soleshared voting power and sole dispositive power over allthese shares. First Light may be deemed to be the beneficial owner of these shares.shares because it acts as an investment adviser to certain private funds. Mr. Arens may also be deemed to be the beneficial owner of these shares because he controls First Light in his position as managing member and majority owner of First Light. The address for OrbiMed Capital LLCbusiness office of each of First Light and Mr. Arens is 601 Lexington Avenue, New York, NY 10022.3300 Edinborough Way, Suite 201, Edina, MN 55435.
(8) Based on a Schedule 13G filed on February 11, 2022,13, 2023, reporting beneficial ownership as of December 31, 2021.2022. Champlain Investment Partners, LLC has sole voting power over 1,536,6401,330,120 of these shares and sole dispositive power over all of these1,743,355 shares. The address for Champlain Investment Partners, LLC is 180 Battery Street Burlington, Vermont 05401.
MANAGEMENT
The following table sets forth certain information with respect to our executive officers as of April 15, 2022.2023.
| | | | | | | | | | | | | | |
| Name | | Age | | Position |
| Laura A. Francis | | 5556 | | Chief Executive Officer |
| Anshul Maheshwari | | 4243 | | Chief Financial Officer |
Michael A. Pisetsky | | 44 | | SVP, Operations and Administration & Chief Legal Officer |
| Anthony J. Recupero | | 6364 | | President, Commercial Operations |
| | | | |
For Ms. Francis’s biography, see “Proposal No. 1 – Election of Directors” above.
Anshul Maheshwari has served as our Chief Financial Officer since April 2021. Prior to joining us, Mr. Maheshwari was Vice President of Finance, Head of Investor Relations and Treasurer at Varian Medical Systems, where he was responsible for and led finance transformation and built finance infrastructure to support growth for a leading, global cancer platform, from June 2018 to April 2021. In April 2013, Mr. Maheshwari joined Bechtel Corporation, the largest U.S.-headquartered engineering and construction company, initially as Manager of Investments and was promoted in June 2014 to Assistant Treasurer responsible for a centralized team managing banking and capital markets, investments, cash management and foreign exchange operations before departing Bechtel in June 2018. From November 2004 to March 2013, Mr. Maheshwari held various roles in Corporate and Investment Banking at Bank of America Merrill Lynch. Mr. Maheshwari received his BCom from H.R. College of Commerce and his M.B.A. from Boston College, Carroll Graduate School of Management.Management
Michael A. Pisetsky has served as our General Counsel and Chief Compliance Officer since August 2016, and as our Senior Vice President of Operations and Administration and Chief Legal Officer since April 2021. Mr. Pisetsky joined us in March 2015 as our Director of Legal. From August 2011 to March 2015, Mr. Pisetsky practiced law privately advising a number of companies in the medical technology, healthcare services and real estate industries. From August 2008 to July 2011, Mr. Pisetsky practiced law in the Business Department at Cooley LLP in Palo Alto, California, representing a number of medical technology, biotech, healthcare services and general technology clients, from inception to public offering or sale. Mr. Pisetsky received his B.A. with Honors from Harvard College, and received his J.D. (magna cum laude) and M.B.A. concurrently from Duke University.
Anthony J. Recupero has served as our President, Commercial Operations since April 2021, and previously served as our Chief Commercial Officer since July 2016. Prior to joining us, Mr. Recupero was the President of Catalyst Performance Advisors, LLC, where he advised leading medical device companies on commercial strategy from June 2013 to July 2016. In July 2008, Mr. Recupero joined Baxano, Inc., a medical device company with minimally invasive products to treat degenerative conditions of the spine affecting the lumbar region, initially as Vice President of Sales and Marketing and was promoted in February 2009 to President and Chief Executive Officer until its acquisition by TranS1 in June 2013. From January 2005 to July 2008, Mr. Recupero was President of Recupero Consulting Group, LLC, where he advised leading medical device companies on commercial strategy. From October 1999 to December 2004, Mr. Recupero was the Vice President of Sales for Kyphon. Early in his career, Mr. Recupero progressed to senior sales management roles at United States Surgical Corporation and Sulzer Spine-Tech, Inc. Mr. Recupero received a B.A. in Communications from State University of New York at Albany.
EXECUTIVE COMPENSATION
Executive Compensation Narrative
This material is intended to assist our stockholders in understanding our executive compensation program by providing an overview of our executive compensation-related policies, practices, and decisions for fiscal 2021.2022. It also explains how we determined the material elements of compensation for our principal executive officer, our former principal executive officer, and our other two executive officers as of the end of fiscal 2021,2022, and who we refer to as our “Named Executive Officers.” For 2021,2022, our Named Executive Officers were:
◦Laura Francis, our Chief Executive Officer (our “CEO”);
◦Anshul Maheshwari, our Chief Financial Officer (our “CFO”); and
◦Anthony Recupero, our President, Commercial Operations;
◦Jeffrey Dunn, our Executive Chairman and former CEO.
We provide an overview of our executive compensation philosophy, the overall objectives of our executive compensation program, and each compensation element that we provide to our Named Executive Officers. In addition, we explain how and why the Compensation Committee of our Board of Directors (the “Compensation Committee”) and, in the case of our Chief Executive Officer, our Board of Directors after receiving the recommendation of our Compensation Committee, arrived at the specific compensation decisions for our Named Executive Officers in 2021.2022.
Overview
We are a global leader in technology for surgical treatment ofmedical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy. In 2009, we introduced the iFuse Implant System for minimally invasive surgery of the SI joint, shown to be a source of pain in 15% to 30% of chronic low back pain. Since then, more than 2,600 surgeonswe have performed a combined totallaunched three new implant product lines to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fusion, fixation and management of more than 65,000 SI joint fusion procedures.pelvic fractures: iFuse-3D in 2017, iFuse-TORQ in 2021 and iFuse Bedrock Granite in 2022. A unique body of evidence supporting the triangular iFuse implant, including two randomized controlled trials and over 100120 peer reviewed publications, has enabled multiple government and private insurance payors to establish coverage of the SI joint fusion procedure exclusively when performed with our triangular iFuse implant. We are leveraging our market leadership position, supported by this proprietary reimbursement advantage, to commercialize other devices intended for surgical treatment of related aspects of the human anatomy.
20212022 Business Highlights
20212022 was a strong year for the company in many critical areas of performance, despite sustained headwindsincluding strong revenue growth, record growth in theour active surgeon base and improving operating environment due to the COVID-19 pandemic.leverage.
•Record worldwide revenue of $90.2$106.4 million, representing a 23%18% increase over 20202021
•U.S. revenue of $82.7$98.8 million, representing a 21%19% increase over 20202021
•Approximately 9,40011,600 US procedures, performed in the US, representing a 25%24% increase over 2020,2021, performed by over 1,0001,300 surgeons
•Over 920 active surgeons in the fourth quarter 2022, approximately 33% increase over the prior year period
•Surpassed 65,00080,000 procedures performed by over 2,6003,000 surgeons worldwide, since inception
•Received near universal coverage ofFDA clearance for iFuse in the United States, with over 35 payors exclusive to iFuseBedrock Granite, a breakthrough device targeting adult deformity, including a New Technology Add-on Payment (NTAP)
•Successfully launched iFuse-TORQ, a highly differentiated 3D-printed threaded implant,Received FDA clearance for pelvic trauma and minimally invasive sacroiliac joint fusion applicationspromotion of general rod compatibility for iFuse Bedrock Granite for adult deformity procedures
•Awarded FDA's Breakthrough Device DesignationReceived FDA clearance for iFuse Bedrock Granitean expanded indication for iFuse-TORQ which includes fixation of pelvic fragility and sacral insufficiency fractures
•Gross marginReceived FDA clearance for iFuse-TORQ to include the Bedrock approach, allowing the promotion of 88%
•Reduced and refinanced outstanding debt withiFuse-TORQ to complement iFuse Bedrock Granite as a new $35 million Term Loan from Silicon Valley Bank at more favorable termssecond point of fixation in the sacro-alar-iliac trajectory
2021 Executive Leadership Transition
In connection with our ongoing succession planning efforts, and as previously disclosed, we undertook an orderly leadership transition that went into effect in April 2021. The following changes to our leadership team occurred at that time:
•Jeffrey Dunn transitioned from Chief Executive Officer to Executive Chairman
•Laura Francis was promoted to Chief Executive Officer
•Anshul Maheshwari joined our company as Chief Financial Officer
•Anthony Recupero was promoted to President, Commercial Operations
This leadership team positions our company for strong execution on key strategic initiatives and the continued creation of stockholder value. Details of the impact on executive compensation of this leadership transition are summarized below and discussed in further detail in the relevant sections below.
20212022 Executive Compensation Highlights
Our approach to executive compensation in 20212022 reflected our measured approach to attracting, retaining, and incentivizing key members of our management team, and aligning their interests with our stockholders. Our overall compensation program consists of three components: base salary, annual cash incentive bonus, and long-term equity incentive compensation. Following are highlights of key compensation actions that were taken with respect to our Named Executive Officers for 2022:
•Base Salaries.We provided our continuing Named Executive Officers with modest 3%6.5% increases in base salary at the beginning of 2021, with further modifications to base salary made only in conjunction with changes in responsibilities,2022, as further described in “Base Salary” below.
•Annual Cash Bonuses.Our annual cash bonus program in 20212022 was based on the achievement of financial goals on financial metrics—revenues, gross margin,– revenue and adjusted EBITDA—EBITDA – and operational metrics relatedmetrics. Adjusted EBITDA excludes from net loss the effects of interest income, interest expense, depreciation and amortization and stock-based compensation. For 2022, our Compensation Committee made the determination to product launches. We set challenging target goals,maintain the same annual cash incentive targets as evidenced by the fact that, despite our strong performance in many respects in 2021, the annual bonus program resulted in a bonus payoutpercentage of 86.27% of target to each ofbase salary for our Named Executive Officers.Officers that had been in place for 2021, except for Mr. Recupero, whose annual cash incentive target was increased from 70% to 75% of his annual base salary. Based on achievement against our 2022 targets, the actual cash incentive compensation payments made to our Named Executive Officers for 2022 represented 98.2% of their target cash bonus opportunities. Details of this program appear in “Annual Cash Bonuses” below.
Our long-term incentives to Named Executive Officers in 2021 were granted in the form of restricted stock units, as detailed in “Long-Term Incentive Compensation” below. These awards align the interests of our Named Executive Officers with stockholders and are at-risk and subject to forfeiture.
Goals of Our Executive Compensation Program
In structuring our executive compensation program, we are guided by the following objectives:
•Competition. We seek to attract, reward, motivate and retain diverse, talented individuals with relevant experience through a competitive pay structure.
•Long-Term Equity Incentive Compensation.Balanced Packages. Our executive compensation program focuses on total compensation, combining short- and long-term components, cash and equity, and fixed and variable payments.
•Align pay with our performance. We tie a substantial portion of executive compensation to Company performance.
•Align with stockholder objectives. We align our executives’ interests with those of our stockholders by linking compensation to corporate performance and corresponding creation of stockholder value.
Adoption of 2022 Performance Share Unit Program, Clawback Policy, and New Stock Ownership Guidelines
For 2022, in addition to granting restricted stock units (RSU) to all NEOs, we have adopted a Performance Share Unit (PSU) program for Ms. Francis and Mr. Maheshwari. Ms. Francis’ 2022 equity grants are issued 50% as PSUs and 50% as RSUs; Mr. Maheshwari’s 2022 equity grants are issued 25% as PSUs and 75% as RSUs. The 2022RSU grants serve to align the interests of management and our stockholders and act as an important retention mechanism, and PSUs, measure the company’swhich are based on SI-BONE’s total shareholder return relative total stockholder return againstto a group of industry peers, promote the achievement of long-term share price growth and relative outperformance. These programs are detailed in equal tranches over one-, two-, and three-year performance periods. In each period, the target performance is the median of the industry peer group. A maximum payout of 200% of target is earned if the company’s performance exceeds the industry group median by 50 percentage points or more; no payout is earned if the company’s performance trails the industry group median by 50 percentage points or more.“Long-Term Incentive Compensation” below.
We adopted a clawback policy in 2021 that enables us to recoup excess cash and equity incentive compensation in the event of an accounting restatement, and enables us to take further recoupment actions in the event of a current or former executive officer’s
misconduct contributing to an accounting restatement. We also strengthened our executive stock ownership guidelines. Further information on these policies is set forth in “Other Compensation Policies” below.
Stockholder Engagement on Executive Compensation
During 2021 and early 2022, we reached out to holders of 52.3%75.1% of our outstanding common stock, seeking to engage with them on executive compensation and other governance topics. We held discussions with holders of 40.2%53.9% of our outstanding common stock, including 8ten of our top 25 stockholders.
We found these discussions to be extremely useful and received valuable feedback on our executive compensation program. Specific items of feedback relating to executive compensation that we heard through these engagements included:
◦•An interest in seeing more detail ondetailed drivers of the annual bonus program and adjustments related to COVID-19 made in determining payouts
◦•Concern aboutAcknowledgement of the provision in Mr. Dunn’s employment agreement providing for a single-trigger severance payment in the event of a change in control
◦An interest in seeing greatercontinued alignment in our long-term incentive awards between the relative returns to our stockholders and the size and value of the equity awards granted to our Chief Executive Officer and Chief Financial Officer
In response to this feedback, we took the following actions:
◦•We are providing additional detail in this proxy statement on the operation of the 20212022 annual bonus program and the factors in the Compensation Committee’s determination of achievement levels, including adjustments made to account for impacts of the COVID-19 pandemic.
◦In October 2021, we amended Mr. Dunn’s employment agreement to eliminate the single-trigger severance provision and replace it with a double-trigger severance provision.
◦We introduced Performance Stock Units for 2022, as detailed in the section above.
◦We adopted a clawback policy, as set forth in “Other Compensation Policies” below.levels.
We intend to continue to initiate dialog with our stockholders on executive compensation and other governance topics. In addition, we welcome stockholder communication with the Board through the channels set forth in this proxy statement.
Emphasis on VariablePay-for-Performance Alignment
We believe our executive compensation program is reasonable and At-Risk Compensationcompetitive, and appropriately balances the goals of attracting, motivating, and retaining a talented leadership team and appropriately rewarding them for their contributions to the business. To ensure our executive officers’ interests are aligned with those of our stockholders, a significant portion of their target total direct cash compensation opportunity each year is “at-risk” and will vary above or below target levels commensurate with our corporate and financial performance. In addition, for 2022, our Named Executive Officers received a substantial amount of equity compensation in the form of RSUs and, for our CEO and CFO, PSUs that further strengthen their long-term alignment with the interests of our stockholders.
We emphasize at-risk compensation that appropriately rewards our executive officers for delivering financial, operational, and strategic results tied to pre-established goals. In addition, our variable programs provide the opportunity for more significant rewards for exceeding these goals, through our cash bonus plan as well as equity awards. The following charts illustrate the pay mix for our Chief Executive Officer and our other Named Executive Officers in 2022:
The annual compensation of our Named Executive Officers varies from year to year based on our corporate financial and operational results. Consistent with our compensation philosophy, our executive compensation program emphasizes “variable” pay over “fixed” pay and seeks to balance short-term and long-term incentives, as well as performance-based and time-based incentives. In 2021,percentages in the majority ofcharts above represent the target total direct compensation offor our CEO consisted of variable pay, including cash awarded under our annual bonus plan and long-term incentives in the form of equity awards, the value of which will be strongly correlated with long-term corporate performance. Fixed pay, primarily consisting of base salary, made up only 15.3% of our CEO’saverage target total direct compensation in 2021, while variable pay, consisting of both annual and long-term incentives in the form of equity awards, made up 84.7% of her target total direct compensation. Similar allocations applied tofor our other Named Executive Officers.Officers for 2022.
Executive Compensation BestGovernance Policies and Practices
We endeavor to maintain sound executive compensation policies and practices, including compensation-related corporate governance standards, consistent with our executive compensation philosophy. During 2021,2022, the following executive compensation policies and practices were in place, including both policies and practices we have implemented to drive performance and policies and practices that either prohibit or minimize behaviors that we do not believe serve our stockholders’ long-term interests:
| | | | | | | | | | | |
| What We Do | | What We Don’t Do |
| ü | Actively engage in year-round dialogue with our stockholders and incorporate feedback into our compensation programs | û | No pension plans or Supplemental Executive Retirement Plans
|
| ü | Significant portion of compensation for Named Executive Officers is at risk, based on both company performance (financial & stock price) and the individual’s performance | û | No hedging or pledging of our securities
|
| ü | Provide compensation mix that more heavily weights variable pay and long-term equity | û | No excise tax gross-ups upon a change of control |
| ü | Stock ownership requirements apply to all Named Executive Officers and directors | û | No significant perquisites to our Named Executive Officers |
| ü | An independent compensation consultant advises the Compensation Committee | û | No single-trigger equity acceleration or excessive severance benefits |
| ü | Annually assess the risk-reward balance of our compensation programs in order to mitigate undue risks in our programs | | |
| ü | Maintain a fully independent Compensation Committee | | |
| ü | We have adopted a clawback policy that provides for the recoupment of incentive compensation in certain situations | | |
| ü | Our Board maintains a robust succession strategy | | |
Compensation Philosophy and Guiding Principles
We have designed our executive compensation program to reward our Named Executive Officers at a level consistent with our overall strategic and financial performance and to provide remuneration sufficient to attract, retain, and motivate them to exert their best efforts in the highly competitive environmentsenvironment in which we operate. We believe that competitive compensation packages consisting of a combination of base salaries, annual cash bonus opportunities, and long-term incentive opportunities in the form of equity awards that are earned over a multi-year period enable us to attract top talent, motivate successful short-term and long-term performance, satisfy our retention objectives, and align the compensation of our executive officers with our performance and long-term value creation for our stockholders.
The Compensation Committee periodically reviews and analyzes market trends and the prevalence of various compensation delivery vehicles and adjusts the design and operation of our executive compensation program from time to time as it deems necessary and appropriate. In designing and implementing the various elements of our executive compensation program, the Compensation Committee considers market and industry practices, as well as the tax efficiency of our compensation structure and its impact on our financial condition. While the Compensation Committee considers all of the factors in its deliberations, it places no formal weighting on any one factor.
As we continue to grow, the Compensation Committee evaluates our compensation philosophy and program objectives as circumstances require. At a minimum, the Compensation Committee reviews executive compensation annually.
Say-on-Pay Vote Results
At our Annual Meeting of stockholders in June 2022, our stockholders had the opportunity to cast an annual advisory vote on the compensation of our Named Executive Officers (commonly known as a “say-on-pay” vote). Approximately 96% of the votes cast on the proposal approved, on an advisory basis, the compensation of our Named Executive Officers as disclosed in last year's proxy statement. Although the vote is non-binding, our Compensation Committee considers the results of the say-on-pay vote when making compensation decisions, allowing our stockholders to provide input on our compensation philosophy, policies and practices. The Compensation Committee believes that our voting results reflect the company's efforts to properly align pay with performance while also aligning management and stockholder interests. We value the opinions of our stockholders, and our Compensation Committee and Board of Directors will continue to consider the outcome of future advisory votes, including the say-on-pay vote which will take place at the Annual Meeting, when making compensation decisions for the Named Executive Officers.
Compensation-Setting Process
Role of the Compensation Committee
The Compensation Committee, among its other responsibilities, establishes our overall compensation philosophy and reviews and approves our executive compensation program, including the specific compensation of our Named Executive Officers. The Compensation Committee has the authority to retain special counsel and other advisors, including compensation consultants, to assist in carrying out its responsibilities to determine the compensation of our executive officers. The Compensation Committee’s authority, duties, and responsibilities are described in its charter, which is reviewed annually and revised and updated as warranted. The charter is available on our Company website at investor.si-bone.com/corporate-governance/governance-highlights.governance-highlights.
While the Compensation Committee determines our overall compensation philosophy and approves (recommends to our Board of Directors in the case of our CEO) the compensation of our Named Executive Officers, it relies on its compensation consultant and legal counsel, as well as members of our management team, including our CEO with respect to Named Executive Officers other than herself. The Compensation Committee makes all final decisions regarding compensation (other than with respect to our CEO, which our Board of Directors determines after receiving the recommendation of our Compensation Committee), including base salary levels, target annual cash bonus opportunities, actual cash bonus payments, and long-term incentives in the form of equity awards. The Compensation Committee meets on a regularly scheduled basis and at other times as needed. The Compensation Committee periodically reviews compensation matters with our Board of Directors.
At the beginning of each year, the Compensation Committee reviews our executive compensation program, including any incentive compensation plans and arrangements, to assess whether our compensation elements, actions, and decisions (i) are (i) properly coordinated, (ii) are aligned with our mission, vision, values, and corporate goals, (iii) provide appropriate short-term and long-term incentives for our executive officers, (iv) achieve their intended purposes, and (v) are competitive with the compensation of executives in comparable positions at the companies with which we compete for executive talent. Following this assessment, the Compensation Committee makes any necessary or appropriate modifications to our existing plans and arrangements or adopts new plans or arrangements.
The Compensation Committee also conducts an annual review of our executive compensation strategy to ensure that it is appropriately aligned with our business strategy and achieving our desired objectives. Further, the Compensation Committee reviews market trends and changes in competitive compensation practices, as further described below. Based on its review and assessment, the Compensation Committee, from time to time, recommends changes in our executive compensation program to our Board of Directors.
The factors considered by the Compensation Committee in determining the compensation of our Named Executive Officers for 20212022 (or recommending to the Board in the case of our CEO) included:
•the recommendations of our CEO (except with respect to her own compensation) as described below;
•our corporate growth and other elements of financial performance;
•our corporate and individual achievements against one or more short-term and long-term performance objectives;
• the individual performance of each Named Executive Officer against his or her management objectives;
•a review of the relevant competitive market analysis prepared by its compensation consultant (as described below);
•the expected future contribution of the individual Named Executive Officer;
•historical compensation awards we have made to our executive officers; and
•internal pay equity based on the impact on our business and performance.
The Compensation Committee did not weight these factors in any predetermined manner, nor did it apply any formulas in making its decisions. The members of the Compensation Committee considered this information in light of their individual experience, knowledge of the company, knowledge of each executive officer, knowledge of the competitive market, and business judgment in making their decisions regarding executive compensation and our executive compensation program.
As part of this process, the Compensation Committee also evaluates the performance of our CEO each year and makes all decisions regarding recommending to the Board her base salary adjustments, target annual cash bonus opportunities, actual cash bonus payments, and long-term incentives in the form of equity awards. Our CEO and Executive Chairman areis not present during any of the deliberations regarding their respectiveher compensation, and no Named Executive Officer is present during any deliberations regarding their compensation.
Role of Our CEO
Our CEO works closely with the Compensation Committee in determining the compensation of our other Named Executive Officers. Typically, our CEO works with the Compensation Committee to recommend the structure of the annual bonus plan, and to identify and develop corporate and individual performance objectives for such plan, and to evaluate actual performance against the selected measures. Our CEO also makes recommendations to the Compensation Committee as described in the following paragraph and is involved in the determination of compensation for the respective executive officers who report to her.
At the beginning of each year, our CEO reviews the performance of our other Named Executive Officers for the previous year, and then shares these evaluations with, and makes recommendations to, the Compensation Committee for each element of compensation. Using her subjective evaluation of each executive officer’s performance and taking into consideration historical compensation awards to our executive officers and our corporate performance during the preceding year, these recommendations concern base salary adjustments, target annual cash bonus opportunities, actual bonus payments, and long-term incentives in the form of equity awards for each of our executive officers (other than herself) based on our results, the individual executive officer’s contribution to these results, and his or her performance toward achieving his or her individual performance goals. The Compensation Committee then reviews these recommendations and considers the other factors described above and makes decisions as to the target total direct compensation of each executive officer (other than our CEO), as well as each individual compensation element.
While the Compensation Committee considers our CEO’s recommendations, as well as the competitive market analysis prepared by its compensation consultant, these recommendations and market data serve as only two of several factors in making its decisions with respect to the compensation of our executive officers. Ultimately, the Compensation Committee applies its own business judgment and experience to determine the individual compensation elements and amount of each element for our executive officers. Moreover, no executive officer participates in the determination of the amounts or elements of his or her own compensation.
Role of Compensation Consultant
Pursuant to its charter, the Compensation Committee has the authority to engage its own legal counsel and other advisors, including compensation consultants, as it determined in its sole discretion, to assist in carrying out its responsibilities. The Compensation Committee makes all determinations regarding the engagement, fees, and services of these advisors, and any such advisor reports directly to the Compensation Committee.
In 2021,2022, pursuant to this authority, the Compensation Committee engaged Compensia, Inc., a national compensation consulting firm, to provide information, analysis, and other assistance relating to our executive compensation program on an ongoing basis. The nature and scope of the services provided to the Compensation Committee by Compensia in 20212022 were as follows:
•developedReviewed and subsequently updated the compensation peer group;
•providedProvided advice with respect to compensation best practices and market trends for compensation of executive officers and members of our Board of Directors;
•conductedConducted an analysis of the levels of overall compensation and each element of compensation for of our Named Executive Officers;
•conducted an analysis of the levels of overall compensationOfficers and each element of compensation for the members of our Board of Directors; and
•provided Provided ad hoc advice and support on compensation and governance topics throughout the year.
Representatives of Compensia attend meetings of the Compensation Committee as requested and also communicate with the Compensation Committee outside of meetings. Compensia reports to the Compensation Committee rather than to management, although Compensia may meet with members of management, including our CEO and members of our executive compensation staff, for purposes of gathering information on proposals that management may make to the Compensation Committee. During 2021, 2022,
Compensia met with various executive officers to collect data and obtain management’s perspective on various executive compensation proposals.
The Compensation Committee may replace its compensation consultant or hire additional advisors at any time. Compensia has not provided any other services to us and has received no compensation other than with respect to the services described above.
The Compensation Committee has assessed the independence of Compensia taking into account, among other things, the various factors as set forth in Exchange Act Rule 10C-1 and the enhanced independence standards and factors set forth in the applicable listing standards of the Nasdaq Stock Market, and has concluded that its relationship with Compensia and the work of Compensia on behalf of the Compensation Committee has not raised any conflict of interest.
Competitive Positioning
Given our unique business profile, history, and market competitors, the Compensation Committee believes that the competitive market for executive talent includes primarily medical device and equipmentcompanies and, to a lesser extent, the broader healthcare sector. Accordingly, it develops a compensation peer group to contain a carefully selected cross-section of such public companies with revenues and market capitalizations that are similar to ours, using factors described below. The Compensation Committee considers the compensation practices of these peer group companies as one factor in its compensation deliberations. This peer group data is supplemented with executive compensation survey data representing both public medical device, technology, and private technologylife sciences companies that are of similar size to SI-BONE, as well as market trends and best practices in executive compensation and the judgment of the Compensation Committee members. Other important factors taken into consideration when determining executive pay levels include employee knowledge, skills and experience; individual performance; scope of responsibilities; and any retention concerns.
2022 Compensation Peer Group
As part of its deliberations,In September 2021, the Compensation Committee, considers competitivewith the assistance of Compensia, approved of the following target criteria for determining the composition of our peer group for purposes of evaluating the compensation of our named executive officers for 2022.
•Revenue: 0.4x to 2.5x our revenue
•Market capitalization: 0.25x to 4.0x our market data on executive compensation levelscapitalization
•Industry: medical device and practices and a related analysis of such data. This data is drawn from a select group of peerequipment
•Location: public companies developedheadquartered in the United States
The following 17 companies were selected by the Compensation Committee as well as compensation survey data.
In August 2019, the Compensation Committee directed its compensation consultant to formulate a group of peer companies to be used as a reference for market positioning and for assessing competitive market practices. The compensation consultant undertook a detailed review of the pool of U.S.-based publicly traded companies, taking into consideration our industry sector as well as the following factors:
•the revenues of the company (focusing on companies with revenues between 0.4x and 2.5x our revenues)
•the market capitalization of the company (focusing on companies between $200 million and $2 billion in market capitalization)
•the comparability of the company’s business model; and
•the comparability of the company’s operating history and maturity.
Following this review, the compensation consultant recommended to the Compensation Committee the followingdefined peer group to consistfor purposes of 15 publicly traded companies, which the Compensation Committee subsequently approved. The selected companies had revenues ranging from $19 million to $382 million, with a median of $90 million, and market capitalizations as of August 2019 ranging from $46 million to $2.0 billion, with a median of $361 million. The companies comprising the2022 executive compensation peer group were as follows:decisions:
| | | | | | | | |
Alphatec Holdings Inc. | GenMark Diagnostics, Inc.Eargo | Nuvectra CorporationSeaSpine Holdings |
Apyx Medical Corporation | Intersect ENT Inc. | OrthoPediatrics Corp.ShockWave Medical |
AxoGen Inc. | iRhythm Technologies, Inc.LeMaitre Vascular | SeaSpine Holdings Corp.Silk Road Medical |
Cerus Corporation | LeMaitre Vascular, Inc. | Surmodics, Inc. |
ConforMIS, Inc. | Misonix, Inc. | ViewRay |
| ConforMIS | NeuroPace | Zynex Inc. |
Cutera Inc. | Nevro Corp. | |
| OrthoPediatrics | |
The Compensation Committee approvedcompanies in this peer group in September 2019.
This compensation peer group was used by the Compensation Committee in connection with its annual review of our executive compensation program for 2020. Specifically, the Compensation Committee reviewed the compensation data drawn from the compensation peer group, in combination with industry-specific compensation survey data, to develop a subjective representation of the “competitive market” with respect to current executive compensation levels and related policies and practices. The Compensation Committee then evaluated how our pay practices and the compensation levels of our executive officers compared to the competitive market. As part of this evaluation, the Compensation Committee also reviewed the performance measures and performance goals generally used within the competitive market to reward performance.
In August 2020, using the same criteria as described above but updating the size criteria (revenue and market capitalization) to align with our then-current size, and to account for the filing by Nuvectra for bankruptcy in the prior year, the compensation consultant evaluated the existing compensation peer group and recommended to the Compensation Committee the following peer group for use in setting 2021 executive compensation, to consist of 15 publicly traded companies, which the Compensation Committee subsequently approved. The selected companies had revenues ranging from $28 million to $178 million, with a median of $79 million, and market capitalizations ranging from $175 million to $1.6 billion, with a median of $536 million. The companies comprising the updated compensation peer group were the same companies as follows:
| | | | | | | | |
Alphatec Holdings, Inc. | GenMark Diagnostics, Inc. | SeaSpine Holdings Corp. |
Apyx Medical Corporation | Intersect ENT, Inc. | Shockwave Medical, Inc. |
AxoGen, Inc. | LeMaitre Vascular, Inc. | Silk Road Medical, Inc. |
Cerus Corporation | Misonix, Inc. | ViewRay, Inc. |
Cutera, Inc. | OrthoPediatrics Corp. | Zynex, Inc. |
The Compensation Committee believesin our peer group for 2021, except that information regarding the compensation practices at other companies is useful in at least two respects. First, the Compensation Committee recognizes that our compensation policiesGenMark Diagnostics was removed because it was acquired, and practices must be competitive in the marketplace. Second, this information is useful in assessing the reasonablenessConformis, Eargo, and appropriateness of individual executive compensation elements and of our overall executive compensation packages. This information is only one of several factors that the Compensation Committee considers, however, in making its decisions with respectNeuroPace were added to the compensation of our executive officers.peer group.
Compensation Elements
The three primary elements of our executive compensation programs are: (1) base salary, (2) annual cash bonus opportunities, and (3) long-term incentives in the form of equity awards, as described below:
| | | | | | | | |
| Compensation Element | What This Element Rewards | Purpose and Key Features of Element |
| Base salary | Individual performance, level of experience, expected future performance and contributions | Provides competitive level of fixed compensation determined by the market value of the position, with actual base salaries established based on the facts and circumstances of each executive officer and each individual position |
| Annual cash bonuses | Achievement of pre-established corporate and individual performance objectives (for 2021, focused on revenue growth, gross margin, adjusted EBITDA, and new product launches, as well as individual contributions and management objectives)for 2022 | Motivate executive officers to achieve critical financial and operational objectives.
Generally, performance levels are established to incentivize our executive officers to achieve or exceed performance objectives. For 2021, payouts forour corporate performance objectives could range from 0% to 125% or 150% for each objective, depending on actual achievement.
and financial short-term goals that are aligned with stockholders' interests |
| Long-term incentives/equity awards | Achievement of corporate and individual performance objectives designed to enhance long-term stockholder value and attract, retain, motivate, and reward executive officers over extended periods for achieving important corporate objectives
Vesting requirements promote retention of highly valued executive officers
| Annual equity awards that provide a variable “at risk” pay opportunity. Restricted stock awardsRSUs vest over four years.years and PSUs granted beginning in 2022, vest over three years.years subject to meeting established total shareholder return ("TSR") performance criteria.
Because the ultimate value of these equity awards is directly related to the market price of our common stock, and the awards are only earned over an extended period of time subject to vesting, they serve to focus management on the creation and maintenance of long-term stockholder value
|
Our Named Executive Officers also participate in the standard employee benefit plans available to most of our employees. In addition, our Named Executive Officers are eligible for modest post-employment (severance and change in control) payments and benefits under certain circumstances. Each of these compensation elements is discussed in detail below, including a description of the particular element and how it fits into our overall executive compensation and a discussion of the amounts of compensation paid to our Named Executive Officers in 20212022 under each of these elements.
Base Salary
We believe that a competitive base salary is a necessary element of our executive compensation program, so that we can attract and retain a stable management team. Base salaries for our Named Executive Officers are also intended to be competitive with those received by other individuals in similar positions at the companies with which we compete for talent, as well as equitable across the executive team.
Generally, we establish the initial base salaries of our Named Executive Officers through arm’s-length negotiation at the time we hire the individual executive officer, taking into account his or her position, qualifications, experience, and the base salaries of our other executive officers.
Thereafter, the Compensation Committee reviews the base salaries of our Named Executive Officers annually and makes adjustments to base salaries (recommends to our Board of Directors in the case of our CEO) as it determines to be necessary or appropriate.
In 2021,2022, the Compensation Committee reviewed the base salaries of our executive officers, taking into consideration a competitive market analysis performed by Compensia and the recommendations of our CEO and Executive Chairman (except with respect to theirher own respective base salaries)salary), as well as the other factors described above. Following this review, the Compensation Committee set (recommended to our Board of Directors in the case of our CEO) the base salaries of our executive officers at levels that it believed were appropriate to maintain their competitiveness.The base salaries of our Named Executive Officers established at the beginning of 20212022 were as follows:
| | | | | | | | | | | |
| Named Executive Officer | 2020 Base Salary | 2021 Base Salary | Percentage Adjustment |
| Laura Francis | $420,000 | $433,0001 | 3% |
| Anshul Maheshwari | N/A2 | $400,000 | N/A |
| Anthony Recupero | $380,000 | $391,0003 | 3% |
| Jeffrey Dunn | $600,000 | $618,0004 | 3% |
(1)In April 2021, the Compensation Committee further increased Ms. Francis’ base salary to $567,000 in conjunction with her promotion to CEO.
(2)Mr. Maheshwari joined the company in April 2021. His base salary was set under the terms of his Offer Letter.
(3)In April 2021, the Compensation Committee further increased Mr. Recupero’s base salary to $430,000 in conjunction with his promotion to President, Commercial Operations.
(4) Mr. Dunn transitioned to Executive Chairman in April 2021, at which time his base salary decreased to $309,000 pursuant to the terms of his amended Offer Letter Agreement and Severance Plan Participation Agreement. | | | | | | | | | | | |
| Named Executive Officer | 2021 Base Salary | 2022 Base Salary | Percentage Adjustment |
| Laura Francis | $567,000 | $604,000 | 6.5% |
| Anshul Maheshwari | $400,000 | $426,000 | 6.5% |
| Anthony Recupero | $430,000 | $458,000 | 6.5% |
The actual base salaries ofearned by our Named Executive Officers during 20212022 are set forth in the “2021“2022 Summary Compensation Table” below.
Annual Cash Bonuses
We use annual bonuses paid to motivate our executive officers, including our Named Executive Officers, to achieve our short-term financial and operational objectives while making progress towards our longer-term growth and other goals. Consistent with our executive compensation philosophy, these annual bonuses are intended to help us to deliver a competitive total direct compensation opportunity to our executive officers.Annual cash bonuses are entirely performance-based, are not guaranteed, and may vary materially from year-to-year.
Typically, the Compensation Committee establishes (recommends to our Board of Directors in the case of our CEO) cash bonus opportunities pursuant to a formal cash bonus plan that measures and rewards our executive officers for our actual corporate performance over ourthe fiscal year. The cash bonus plan is designed to pay above-target bonuses when we exceed our annual corporate objectives and below-target bonuses (or no bonuses) when we do not achieve these objectives.
In January 2021,2022, the Compensation Committee determined to award (recommend to our Board of Directors in the case of our CEO) cash bonus opportunities to our Named Executive Officers, pursuant to the cash bonus plan for 2021.2022. The Compensation Committee has the authority to select the performance measures and related target levels applicable to the annual cash bonus opportunities for our executive officers. The performance measures involving our financial results could be determined in accordance with GAAP, or such financial results could consist of non-GAAP financial measures, and any actual results were subject to adjustment by the Compensation Committee for one-time items or unbudgeted or unexpected items when determining whether the target levels for the performance measures had been met.
Under the 2021 bonus plan, the Compensation Committee could,may also, in its sole discretion, and at any time, increase, reduce, or eliminate a participant’s actual bonus payment, and/or increase, reduce, or eliminate the amount allocated to the bonus pool for the year. Further, the actual bonus payment could be below, at, or above a participant’s target bonus opportunity, in the Compensation Committee’s sole discretion. The Compensation Committee could determine the amount of any reduction on the basis of such factors as it deemed relevant, and it was not required to establish any allocation or weighting with respect to the factors it considers.payment.
Target Bonus Opportunities
In January 2021, theThe 2022 target annual cash bonus opportunities for each of our Named Executive Officers under the 20212022 bonus plan, expressed as a percentage of his or her annual base salary, were as follows. Adjustments made in April 2021 in conjunction with our leadership transition are noted below the table.follows:
| | | | | | | | | | | | | | | | | | | | | | | |
| Named Executive Officer | January 2021 Base Salary | January 2021 Target Bonus Opportunity Percentage | Portion of 2021 at This Level | Base Salary Effective April 20, 2021 | April 2021 Target Bonus Opportunity Percentage | Portion of 2021 at This Level | Total 2021 Target Bonus Opportunity ($) |
Laura Francis1 | $433,000 | 55% | 0.3 | $567,000 | 85% | 0.7 | $408,995 |
Anshul Maheshwari2 | N/A | N/A | N/A | $400,000 | 45% | 0.7 | $126,136 |
Anthony Recupero3 | $391,000 | 65% | 0.3 | $430,000 | 70% | 0.7 | $286,980 |
Jeffrey Dunn4 | $618,000 | 100% | 0.3 | $309,000 | 100% | 0.7 | $401,470 |
(1)In April 2021, Ms. Francis’ base salary increased to $567,000, and her target bonus opportunity increased to 85% of base salary, in conjunction with her promotion to CEO.
(2)Mr. Maheshwari joined the company in April 2021. His target bonus opportunity was set under the terms of his Offer Letter.
(3)In April 2021, Mr. Recupero’s base salary increased to $430,000, and his target bonus opportunity increased to 70% of base salary, in conjunction with his promotion to President, Commercial Operations.
(4)In April 2021, Mr. Dunn’s base salary decreased to $309,000 in conjunction with his transition to Executive Chairman, and his target bonus opportunity was adjusted to 100% of his new base salary. | | | | | | | | | | | |
| Named Executive Officer | 2022 Base Salary | 2022 Target Bonus Percentage | Total 2022 Target Bonus Opportunity ($) |
| Laura Francis | $604,000 | 85% | $513,400 |
| Anshul Maheshwari | $426,000 | 45% | $191,700 |
| Anthony Recupero | $458,000 | 75% | $343,500 |
The target annual cash bonus opportunities of our executive officers, including the Named Executive Officers, were driven entirely by achievement of corporate financial and operational objectives. The Compensation Committee determined this allocation to be appropriate to focus our executive officers on our short-term financial objectives as reflected in our annual operating plan while, at the same time, recognizing their contributions to the achievement of these objectives and the successful execution of their individual roles and responsibilities.
Corporate Performance Objectives
For purposes of the 20212022 bonus plan, the Compensation Committee selected the following as the corporate performance measures.
◦Revenues,Revenue, weighted 50%40%, utilizing quarterly goals due to uncertainty caused by the COVID-19 pandemic
◦Gross margin, weighted 10%pandemic;
◦Adjusted EBITDA, (adjusted forweighted 10%, utilizing quarterly goals due to uncertainty caused by the impact of stock-based compensation), weighted 10%COVID-19 pandemic;
◦TORQ U.S. launch,Active annual surgeon growth, weighted 15%10%;
◦iFuseNew product (iFuse Bedrock Granite U.S. launch,first in patient) milestones, weighted 15%20%;
◦Clinical (SAFFRON sacral fracture study first patient enrolled) milestones, weighted 10%; and
◦Voluntary attrition rate, weighted 10%.
The Compensation Committee believed these performance measures were appropriate for our business because they providedprovide a balance between generating revenue, managing our expenses, and growing our business, which it believes most directly influencesinfluence long-term stockholder value. At the same time, the Compensation Committee established target performance levels for each of these measures at levels that it believed to be challenging, but attainable, through the successful execution of our annual operating plan.The Compensation Committee chose to use quarterly revenuesrevenue and adjusted EBITDA goals set at the beginning of each quarter due to the difficulty in planning or forecasting annual revenue as a result of the dynamic and uncertain operating environment caused by the COVID-19 pandemic.
The minimum,threshold, target, and maximum levels of achievement for each corporate performance measure and their respective payment amounts, with the actual bonus payment with respect to each measure to be determined independently, were as follows:
| | | | | | | | | | | | | | | | | | | | |
| Corporate Performance Measure | Threshold Performance Level | Threshold Payment Level | Target Performance Level | Target Payment Level | Maximum Performance Level | Maximum Payment Level |
| Revenues | $90.5M | 50% | $96.0M | 100% | $101.5M | 150% |
| Gross margin | 86% | 80% | 87% | 100% | 88% | 125% |
| Adjusted EBITDA | ($39M) | 80% | ($37M) | 100% | ($35M) | 125% |
| TORQ U.S. Launch | June 2021 | 80% | May 2021 | 100% | April 2021 | 125% |
| iFuse Bedrock Granite U.S. Launch | December 2021 | 80% | November 2021 | 100% | October 2021 | 125% |
| | | | | | | | | | | | | | | | | | | | | | | |
| Corporate Performance Measure | Weight | Threshold Performance Level | Threshold Payout Level | Target Performance Level | Target Payout Level | Maximum Performance Level | Maximum Payment Level |
| Revenue (set quarterly) | 40 | % | $101.0M | 50% | $109.8M | 100% | $118.5M | 150% |
| Adjusted EBITDA (set quarterly) | 10 | % | ($36M) | 80% | ($32M) | 100% | ($28M) | 125% |
| Active Annual Surgeon Growth | 10 | % | +10% | 80% | +15% | 100% | +20% | 125% |
| Granite (first in patient) | 20 | % | July | 80% | June | 100% | May | 125% |
| SAFFRON Study (initiated) | 10 | % | October | 80% | September | 100% | August | 125% |
| Voluntary Attrition Rate (year over year) | 10 | % | Down 1% | 80% | Down 2% | 100% | Down 4% | 125% |
In the event of actual performance between the threshold and target, and target and maximum, performance levels, the payment amount was to be calculated between each designated segment on a linear basis.
20212022 Performance Results and Bonus Decisions
In January 2022,2023, the Compensation Committee approved (recommended to our Board of Directors in the case of our CEO) our actual achievement with respect to the corporate financialperformance objectives under the 20212022 bonus plan as follows:
| | | | | | | | | | | | | | |
| Corporate Performance Measure | Actual Achievement | Achievement Payout Level | Weighting | Bonus Contribution |
| Revenues | $92.4M1 | 70% | 50% | 35.02% |
| Gross margin | 88% | 125% | 10% | 12.50% |
| Adjusted EBITDA | Greater than ($35M) | 125% | 10% | 12.50% |
| TORQ U.S. Launch | April | 125% | 15% | 18.75% |
| iFuse Bedrock Granite U.S. Launch | N/A2 | 50% | 15% | 7.50% |
| | | Total | 86.27% |
| | | | | | | | | | | | | | |
| Corporate Performance Measure | Weight | Actual Achievement | Achievement Payout Level | Bonus Contribution |
| Revenue (set quarterly) | 40% | $106.4M | 80.0% | 32.0% |
| Adjusted EBITDA (set quarterly) | 10% | ($33M) | 75.4% | 7.5% |
| Active Annual Surgeon Growth | 10% | 1,327 | 125.0% | 12.5% |
| Granite (first in patient) | 20% | May | 125.0% | 25.0% |
| SAFFRON Study (initiated) | 10% | September | 100.0% | 10.0% |
| Voluntary Attrition Rate (year over year) | 10% | Down 2.9% | 111.4% | 11.2% |
| | | Total | 98.2% |
(1)Includes aggregate add-back of $2.2M in identified case revenue that were deferred in Q3 and Q4 related to COVID-19.
(2) The company did not attain U.S. launch for iFuse Bedrock Granite in 2021 due to supply chain constraints related to the COVID-19 pandemic. However, because of the FDA's designation of iFuse Bedrock Granite as a Breakthrough Device in November 2021, the Compensation Committee determined to award 50% achievement on this metric.
The Compensation Committee determined that, based on our actual performance with respect to each corporate performance measure, the corporate performance objectives had been achieved, in the aggregate, at an 86.27%98.2% level. Accordingly, the Compensation Committee (our Board of Directors in the case of our CEO) approved bonus payments as follows for our Named Executive Officers and our Executive Chairman:Officers:
| | | | | | | | | | | |
| Named Executive Officer | Target Annual Cash Bonus Opportunity | Bonus Achievement Percentage | Actual Annual Cash Bonus Payment |
| Laura Francis | $408,995 | 86.27% | $352,840 |
| Anshul Maheshwari | $126,136 | 86.27% | $108,818 |
| Anthony Recupero | $286,980 | 86.27% | $247,578 |
| Jeffrey Dunn | $401,470 | 86.27% | $346,345 |
| | | | | | | | | | | |
| Named Executive Officer | Target Annual Cash Bonus Opportunity | Bonus Achievement Percentage | Actual Annual Cash Bonus Payment |
| Laura Francis | $513,400 | 98.2% | $504,159 |
| Anshul Maheshwari | $191,700 | 98.2% | $188,249 |
| Anthony Recupero | $343,500 | 98.2% | $337,317 |
The actual annual cash bonuses paid to our Named Executive Officers for 20212022 are also set forth in the “2021“2022 Summary Compensation Table” below.
Long-Term Incentive Compensation
We use long-term incentive compensation in the form of equity awards to motivate our executive officers, including our Named Executive Officers, by providing them with the opportunity to build an equity interest in the company and to share in the potential appreciation of the value of our common stock. The Compensation Committee views equity awards, whether the awards are subject to time-based vesting requirements or are to be earned based on the attainment of specific performance objectives, areas inherently variable since the grant date fair value of these awards may not necessarily be indicative of their value when, and if, the shares of our common stock underlying these awards are ever earned or purchased.vested. The Compensation Committee further believes these awards enable us to attract and retain key talent in our industry and alignsalign our executive officers’ interests with the long-term interests of our stockholders.
Generally, in determining the size of the equity awards granted to our executive officers, the Compensation Committee takes into consideration the recommendations of our CEO and Executive Chairman (except with respect to theirher own respective equity awards), as well asand other factors, including the factors described above.comparative awards granted to similar positions at our peer companies, the performance and expected performance of the executive officer, the existing equity holdings of each executive officer, including the current economic value of their unvested equity awards and the ability of these unvested holdings to satisfy our retention objectives, overall market data, and information provided by our compensation consultant. The Compensation Committee also considers the dilutive effect of our long-term incentive compensation practices, and the overall impact that these equity awards, as well as awards to other employees, will have on stockholder value.
In January 2021,2022, the Compensation Committee approved(our Board of Directors in the case of our CEO) granted equity awards for our Named Executive Officers. In determiningin the amountform of each Named Executive Officer’s equity award, the Compensation Committee took into consideration the recommendations of our then-serving CEO (except with respect to his own equity award), as well as the factors described above. The Compensation Committee also considered the existing equity holdings of each executive officer, including the current economic value of their unvested equityrelative total shareholder return (“TSR”) PSU awards and the ability of these unvested holdings to satisfy our retention objectives. In April 2021, the Board approved equity awards to Mr. Maheshwari upon his joining the company.
These equity awards consisted of RSU awards that may be settled for shares of our common stock. The Compensation Committee also granted additional equity awards to Ms. Francis and Mr. Recupero in conjunctionMaheshwari, and RSU awards to Mr. Recupero. Further, the Compensation Committee determined Ms. Francis’ 2022 long-term incentive mix would be 50% PSUs and 50% RSUs, and Mr. Maheshwari’s mix would be 25% PSUs and 75% RSUs. By using a mix of PSU awards and RSU awards, the Compensation Committee sought to balance a high-performance threshold (in the case of PSU awards whose value depends on how our stock performs against an index), while using RSU awards to provide a strong retention incentive even if our stock price does not perform well relative to the index. The Compensation Committee determined the mix of RSUs and PSUs for each of our Named Executive Officers with their promotions during 2021.reference to market norms and predominant practices among our peer companies. The equity awards granted to our Named Executive Officers in 20212022 were as follows:
| | | | | | | | | | | |
| Named Executive Officer | Number of RSUs | Target Number of Relative TSR PSUs | Total Target Value1 |
| Laura Francis | 63,865 | 127,728 | $2,750,000 |
| Anshul Maheshwari | 41,802 | 27,868 | $1,200,000 |
| Anthony Recupero | 69,770 | — | $1,500,000 |
(1) The amounts reported in this column represent the target value of equity awards made in 2022. This differs from the aggregate grant date fair value of awards as computed in accordance with FASB ASC 718 and reported in the “2022 Summary Compensation Table” below.
The PSU awards granted to Ms. Francis and Mr. Maheshwari are designed to be earned based on our TSR as compared to a group of industry peers in equal tranches over one-, two-, and three-year performance periods. In each period, the target performance is the median of the industry peer group. A maximum payout of 200% of target is earned if the company’s performance exceeds the industry group median by 50 percentage points or more; no payout is earned if the company’s performance trails the industry group median by 50 percentage points or more.
| | | | | |
Named Executive Officer | Number of Restricted Stock Units | |
| Achievement Level | Performance Laura Francis(Points vs. 501th Percentile Company)
| 82,244Payout (% of Target) |
| Maximum | ≥ +50 Point | 200% |
| Target | Anshul MaheshwariEqual to 502th percentile company
| 38,240100% |
Anthony Recupero3
Threshold | 59,552 |
Jeffrey Dunn4
-50 Point | 126,000 (63,000 forfeited in April 2021)0% |
(1) Consists
The 2022 PSUs include interim payout opportunities after the end of 49,280the first and second years of the three-year performance period. The first interim payout opportunity is capped at one-third of the target level payout for the PSUs, while up to 200% of the target shares grantedassociated with the second-year performance period may be earned following that performance period, based on January 5, 2021, 100relative TSR performance and continued service through the end of the relevant year. Up to 200% of the total target shares grantedunder the whole award may be earned after the conclusion of the three-year performance period based on March 4, 2021,relative TSR performance through the end of the three-year performance period, less any shares previously earned and 32,864 shares granted on April 18, 2021, in conjunction with Ms. Francis’ promotion to CEO.paid out for the first and second interim periods.
(2) Granted April 21, 2021, in conjunction with Mr. Maheshwari’s hiring.
(3) Consists of 49,280 shares granted on January 5, 2021, and 10,272 shares granted on April 19, 2021, in conjunction with Mr. Recupero’s promotion to President, Commercial Operations.
(4) Mr. Dunn forfeited 50% of this award in conjunction with his transition to Executive Chairman.
The RSU awards granted to our Named Executive Officers in January and April 20212022 were subject to a time-based vesting requirement providing that these awards are to vest quarterly over four years, assuming the continued service of the executive officers on each such vesting date.
The number and value of equity awards granted to our Named Executive Officers in 2021 are set forth in the “2021 Summary Compensation Table” and the “2021 Grants of Plan-BasedEarned PSU Awards Table” below.
We adopted a new long-term incentive compensation structure forAs noted above, the 2022 in which certain Named Executive Officers receive a combination of restricted stock units and performance share units. DetailsPSUs include an interim payout opportunity after the end of the first year of the three-year performance period, capped at one-third of the target level payout for the PSUs, based on relative TSR performance and continued service through the end of the first year. For the first year covered by the 2022 performance sharePSUs, we achieved a payout of 100% of target shares associated with the first tranche of the award. In 2022, we outperformed on a TSR basis the median issuer in our designated peer group, such that participants in our PSU program are set forthwould have earned 134% of the target shares eligible for release in February 2023 but for the “Overview” section above.cap of 100% on Year 1 achievement specified in our PSU grants.
Welfare and Health Benefits
We provide medical and life insurance benefits to our Named Executive Officers, on the same basis as all of our full-time employees. These benefits include health, dental and vision benefits, health and dependent care flexible spending accounts, short-term and long-term disability insurance, accidental death and dismemberment insurance, and basic life insurance coverage. These benefits are provided on the same basis as all of our full-time employees, therefore are excluded from the Summary Compensation table. We also
provide vacation and other paid holidays to all employees, including our executive officers. We do not offer our employees a non-qualified deferred compensation plan or pension plan.
We design our employee benefits programs to be affordable and competitive in relation to the market, as well as compliant with applicable laws and practices. We adjust our employee benefits programs as needed based upon regular monitoring of applicable laws and practices, the competitive market and our employees' needs.
Perquisites and Other Personal Benefits
Currently, we do not view perquisites or other personal benefits as a significant component of our executive compensation program. Accordingly, we do not provide perquisites to our executive officers, except in situations where we believe it is appropriate to assist an individual in the performance of his or her duties, to make our executive officers more efficient and effective, and for recruitment and retention purposes. During 2021,2022, none of the Named Executive Officers received perquisites or other personal benefits that were, in the aggregate, $10,000 or more for such Named Executive Officer.Officer.
In the future, we may provide perquisites or other personal benefits to our executive officers in limited circumstances, such as where we believe it is appropriate to assist an individual executive officer in the performance of his or her duties, to make our executive officers more efficient and effective, and for recruitment, motivation or retention purposes. We do not expect that these perquisites or other personal benefits will be a significant aspect of our executive compensation program. All future practices with respect to perquisites or other personal benefits will be approved and subject to periodic review by the Compensation Committee.
SI-BONE, Inc. Severance Benefit Plan
On July 16, 2020, the Compensation Committee of our Board of Directors of SI-BONE, Inc. adopted the SI-BONE, Inc. Severance Benefit Plan (the “Severance Plan”), and form of Participation Agreement for use with the Severance Plan, pursuant to which participants in the Severance Plan, including our Named Executive Officers, will receive severance benefits if we terminate the participant’s employment with us without “cause” or the participant resigns his or her employment for “good reason” within three months prior to, or within 12 months following, a “change in control” of SI-BONE (as such terms are defined in the Severance Plan). In addition, our Executive Chairman, Jeffrey Dunn, will receive benefits under the Severance Plan if the closing of a “change in control” occurs and he agrees to provide transition services to us on a full-time basis for up to six months following the “change in control.” Participants in the Severance Plan are those employees that have been designated as participants by the Board of Directors or Compensation Committee as participants in the Severance Plan and who have signed a Participation Agreement. All of our Named Executive Officers have been designated as participants in the Severance Plan.
Severance payments to our Named Executive Officers in connection with a change in control are as follows: (1) a lump sum cash payment equal to 12 months base salary (24(18 months in the case of Mr. Dunn)Ms. Francis), (2) a lump sum cash payment of the then current annual target cash bonus (1.5 times annual target cash bonus in the case of Mr. Dunn)Ms. Francis), (3) COBRA coverage for 12 months (24(18 months in the case of Mr. Dunn)Ms. Francis), (4) full acceleration of vesting of all equity awards, and (5) extension of the post-termination exercise period to two years (or the closing of the change in control if provided in the equity award or change in control agreement). On April 18, 2021, in connection with Ms. Francis becoming Chief Executive Officer, the Board of Directors approved augmenting her severance payments in connection with a change in control to include: a lump sum cash payment equal to 18 months base salary and a lump sum cash payment of 1.5 times the then current annual target cash bonus.
In addition, in the event SI-BONE terminates the employment of an executive officer without cause other than within three months prior to or 12 months following a change in control, the executive officer will receive severance payments as follows: (1) a lump sum cash payment equal to 12 months base salary, and COBRA coverage for 12 months.
To obtain benefits under the Severance Plan the participant must sign and deliver to SI-BONE a release of liability in favor of SI-BONE.
Employment Arrangements
We have offer letters with each of our Named Executive Officers. The offer letters generally provide for at-will employment and set forth the executive officer’s initial base salary, eligibility for employee benefits and confirmation of the terms of previously issued equity grants, including in some cases severance benefits on a qualifying termination of employment. In addition, each of our executive officers has executed our standard proprietary information and inventions agreement. With the exception of Mr. Dunn, as described further below, anyAny severance provisions of the Named Executive Officers’ offer letters were superseded by the Severance Plan.
During 2021, we entered into new or modified offer letters with two of our Named Executive Officers, as described below.
Anshul Maheshwari
In April 2021, we entered into an offer letter with Mr. Maheshwari, which provides for a $400,000 annual base salary, a target bonus of up to 45% of his base salary, and a grant of 38,240 RSUs. The offer letter also provides for a sign-on bonus of $75,000 and eligibility to participate in the Severance Plan.
Jeffrey W. Dunn
In January 2021, we entered into amendment of Mr. Dunn’s 2009 offer letter and severance plan participation agreement, pursuant to which upon the transition effective on the earlier of either the hiring of a new Chief Financial Officer or May 1, 2021, (a) Mr. Dunn would become Executive Chairman and his time commitment to us would be reduced to 50% of his full working time prior to the transition; (b) Mr. Dunn would serve in the capacity of Executive Chairman until the earlier of the date on which the Board determines that he shall no longer serve in such capacity and May 1, 2023, at which point his employment with us would end and Mr. Dunn would transition to our non-Executive Chairman; (c) Mr. Dunn’s base salary would be $309,000 per year, which is fifty percent (50%) of his base salary immediately preceding the transition, and his target annual bonus would be 100% of base salary, and (d) 50% of the unvested portion of the equity award granted to Mr. Dunn on January 5, 2021 was forfeited. This amendment took effect upon Mr. Maheshwari’s start date with the company.
In October 2021, we entered into a second amendment to Mr. Dunn’s offer letter and severance plan participation agreement, in which we eliminated Mr. Dunn’s ability to receive “single trigger” cash severance benefits upon a change in control and specified that he would receive such benefits only upon a Covered Termination occurring during the Change in Control Period (each as defined in the Severance Plan). This second amendment also modifies the definition of “Good Reason” to be triggered with respect to Mr. Dunn if he ceases to be Chairman of the Board during the Change in Control Period or, following a change in control, the chairman of the board of the successor entity.
Other Compensation Policies
Stock Ownership Policy
We believe that stock ownership by our executive officers, including our Named Executive Officers, is important to link the risks and rewards inherent in stock ownership of these individuals and our stockholders. The Compensation Committee has adopted a stock ownership policy that requires our executive officers to own a minimum number of shares of our common stock. These mandatory ownership levels are intended to create a clear standard that ties a portion of these individuals’ net worth to the performance of our stock price. The current ownership requirements are as follows:
| | | | | |
| Named Executive Officer | Minimum Required Level of Stock Ownership |
| Chief Executive Officer | Value equivalent to three times annual salary |
| Other Executive Officers | Value equivalent to annual salary |
Shares that count toward satisfaction of these ownership requirements include shares owned by the executive, including shares purchased on the open market. Unexercised options and unvested RSUs and PSUs do not count toward these ownership requirements. Executives have five years to comply with the applicable stock ownership requirement.
As of the end of fiscal 2021,year 2022, our CEO and each of our other Named Executive Officers had satisfied his or her required stock ownership level or werewas on track to do so.
Compensation Recoupment Policy
In 2021, the company adopted a clawback policy providing that, if the company is required to prepare an accounting restatement for any quarter or year commencing after adoption of the policy, we shall recover from any current executive officer the full amount of the difference between any cash or equity incentive compensation based in whole or in part on the attainment of a financial reporting measure that was received by the executive officer and that the executive officer would have been entitled to had the financial statements been properly reported. In addition, if a current or former executive officer’s misconduct contributed to the obligation to restate our financial statements, we may recover for three years from the date we were required to prepare an accounting restatement the excess incentive compensation paid to that executive officer and recoup excess sales proceeds from the sale of any shares of our stock acquired pursuant to an award granted under our equity incentive plans.
Hedging and Pledging Policies
Under our Insider Trading Policy, no director, employee or consultant to SI-BONE may engage in short sales, transactions in put or call options, hedging transactions, margin accounts, pledges, or other inherently speculative transactions with respect to our stock at any time.
Tax and Accounting Considerations
The Compensation Committee takes the applicable tax and accounting requirements into consideration in designing and overseeing our executive compensation program.
Deductibility of Executive Compensation
For federal income tax purposes, publicly traded companies may be prohibited from deducting employee remuneration in excess of $1 million paid to certain “covered employees,” which may include certain Named Executive Officers, including, but not limited to, our Chief Executive Officer and Chief Financial Officer, under Section 162(m) of the Internal Revenue Code (the “Code”). Even if Section 162(m) may limit the compensation deduction, our Board of Directors and the Compensation Committee believe our compensation policies and practices should be designed to help us meet our established goals and objectives. While the Compensation Committee will consider the impact of the Section 162(m) deduction limitation, it intends to continue to compensate our executive officers, including our Named Executive Officers, in a manner that is in the best interest of our stockholders and reserves the right to make compensation decisions that may not be deductible under Section 162(m) where the Compensation Committee determines the compensation to be appropriate and in the best interests of the company and our stockholders.
Section 409A Considerations
Section 409A of the Code affects the manner by which deferred compensation opportunities are offered to our employees because Section 409A requires, among other things, that “non-qualified deferred compensation” be structured in a manner that limits employees’ ability to accelerate or further defer certain kinds of deferred compensation. We intend to operate our existing
compensation arrangements that are covered by Section 409A in accordance with the applicable rules thereunder, and we will continue to review and amend our compensation arrangements where necessary to comply with Section 409A.
Accounting for Stock-Based Compensation
The Compensation Committee takes accounting considerations into account in designing compensation plans and arrangements for our executive officers and other employees. Chief among these is ASC Topic 718, the standard which governs the accounting treatment of certain stock-based compensation. Among other things, ASC Topic 718 requires us to record a compensation expense in our income statement for all equity awards granted to our executive officers and other employees. This compensation expense is based on the grant date “fair value” of the equity award and, in most cases, will be recognized ratably over the award’s requisite service period (which, generally, will correspond to the award’s vesting schedule). This compensation expense is also reported in the compensation tables below, even though recipients may never realize any value from their equity awards.
37Compensation Risk Assessment
In consultation with management and Compensia, our Compensation Committee’s independent compensation consultant, in September 2022 our Compensation Committee assessed our compensation plans, policies and practices for our Named Executive Officers and other employees and concluded that they do not create risks that are reasonably likely to have a material adverse effect on our company. This risk assessment included, among other things, a review of our cash and equity incentive-based compensation plans to ensure that they are aligned with our company performance goals and overall target total direct compensation to ensure an appropriate balance between fixed and variable pay components. Our Compensation Committee conducts this assessment annually.
SUMMARY COMPENSATION TABLESummary Compensation Table
The following table shows for the fiscal years ended 20212022 and 20202021 compensation awarded to or paid to, or earned by, our Named Executive Officers.
SUMMARY COMPENSATION TABLESummary Compensation Table
| | Name and Principal Position | Name and Principal Position | | Year | | Salary | | Stock Awards(1) | | Non-Equity Incentive Plan Compensation(2) | | Total | Name and Principal Position | | Year | | Salary | | Stock Awards(1) | | Non-Equity Incentive Plan Compensation(2) | | Total | |
Jeffrey W. Dunn(3) | | 2021 | | $ | 401,466 | | | $ | 3,599,820 | | | $ | 346,345 | | | $ | 4,347,631 | | |
| Executive Chairman and Director | | 2020 | | $ | 555,000 | | | $ | 3,119,260 | | | $ | 544,199 | | | $ | 4,218,458 | | |
| Laura A. Francis(3) | Laura A. Francis(3) | | 2021 | | $ | 526,902 | | | $ | 2,550,899 | | | $ | 352,840 | | | $ | 3,430,641 | | Laura A. Francis(3) | | 2022 | | $ | 604,000 | | | $ | 3,785,800 | | | $ | 504,159 | | | $ | 4,893,959 | | |
| Chief Executive Officer | Chief Executive Officer | | 2020 | | $ | 386,250 | | | $ | 1,182,985 | | | $ | 209,517 | | | $ | 1,778,752 | | Chief Executive Officer | | 2021 | | $ | 526,902 | | | $ | 2,550,899 | | | $ | 352,840 | | | $ | 3,430,641 | | |
| | Anthony J. Recupero | Anthony J. Recupero | | 2021 | | $ | 418,330 | | | $ | 1,764,265 | | | $ | 247,578 | | | $ | 2,430,173 | | Anthony J. Recupero | | 2022 | | $ | 458,000 | | | $ | 1,561,228 | | | $ | 337,317 | | | $ | 2,356,545 | | |
| President, Commercial Operations | President, Commercial Operations | | 2020 | | $ | 342,500 | | | $ | 1,187,110 | | | $ | 224,029 | | | $ | 1,753,639 | | President, Commercial Operations | | 2021 | | $ | 418,330 | | | $ | 1,764,265 | | | $ | 247,578 | | | $ | 2,430,173 | | |
| Anshul Maheshwari(4)
| Anshul Maheshwari(4)
| | 2021 | | $ | 280,303 | | | $ | 1,330,752 | | | $ | 108,818 | | | $ | 1,719,873 | | Anshul Maheshwari(4)
| | 2022 | | $ | 426,000 | | | $ | 1,516,636 | | | $ | 188,249 | | | $ | 2,130,885 | | |
| Chief Financial Officer | Chief Financial Officer | | Chief Financial Officer | | 2021 | | $ | 280,303 | | | $ | 1,330,752 | | | $ | 108,818 | | | $ | 1,719,873 | | |
(1) Represents the aggregate grant date fair value of restricted stock units granted to the officer, computed in accordance with FASB ASC Topic 718. The fair value of the restricted stock units is based on the market price of our common stock on the date of grant. We did not grant any stock options in 2021.2021 and 2022.
(2) Represents payments upon the achievement of 20212022 and 20202021 corporate goals, as applicable, as well as individual objectives, which were paid in January 20222023 and January 2021,2022, respectively. Our 2022 corporate goals included revenue growth, gross margin, profitability management, andsurgeon growth rates, product roadmap milestones.milestones, and attrition rates. We did not modify these goals during 2021, due to the extent of the ongoing uncertainty for our business related to COVID-19. However, in January 2022, in finalizing the revenue goal for the 2021 bonus compensation, the Compensation Committee modified the metrics for the revenue goal, taking into account the unique and significant impact of COVID-19 on our revenue, as well as our management team’s effective response successfully navigating the pandemic. In addition, the Compensation Committee awarded partial achievement under one of the two product roadmap milestones due to COVID-related supply challenges impacting our second-generation deformity product and exceptional work in other aspects of commercialization of this product.2022.
(3) Mr. Dunn became our Executive Chairman and ceased to be our President and Chief Executive Officer, and Ms. Francis became our Chief Executive Officer, in April 2021.
(4) Mr. Maheshwari became our Chief Financial Officer in April 2021, replacing Ms. Francis in that role.
OUTSTANDING EQUITY AWARDS AT DECEMBEROutstanding Equity Awards at December 31, 20212022
The following table shows, certain information regarding outstanding equity awards at December 31, 2021,2022, for our Named Executive Officers:
| | | Option Awards(1) | | Stock Awards | |
| | Vesting Commencement Date | | Number of Securities Underlying Unexercised Options Vested (#) | | Number of Securities Underlying Unexercised Options Unvested (2)(#) | | Option Exercise Price
($) | | Option Expiration Date | | Number of Shares or Units of Stock That Have Not Vested (#) | | Market Value of Shares or Units of Stock That Have Not Vested(3) ($) | |
| Jeffrey W. Dunn | | 07/21/14 | | 272,753 | | — | | | 3.42 | | 07/21/24 | | — | | | — | | |
| 04/15/15 | | 26,340 | | — | | | 4.32 | | 05/25/25 | | — | | | — | | |
| 06/02/16 | | 114,901 | | — | | | 4.32 | | 07/26/26 | | — | | | — | | |
| 09/06/17 | | 126,260 | | — | | | 4.68 | | 03/01/27 | | — | | | — | | |
| 01/15/19 | | 107,552 | | 39,948 | | 22.00 | | 01/15/29 | | 21,281 | | 472,651 | | |
| — | | — | | | — | | | — | | | — | | | 76,925 | | 1,708,504 | | |
| — | | — | | | — | | | — | | | — | | | 51,194 | | 1,137,019 | | |
| | | | | | | Option Awards(1) | | Stock Awards | | Equity Incentive Plan Awards (4) |
| | | | | | Grant Date | | Vesting Commencement Date | | Number of Securities Underlying Unexercised Options Vested (#) | | Number of Securities Underlying Unexercised Options Unvested (2)(#) | | Option Exercise Price
($) | | Option Expiration Date | | Number of Shares or Units of Stock That Have Not Vested (#) | | Market Value of Shares or Units of Stock That Have Not Vested(3) ($) | | Number of Shares or Units of Stock That Have Not Vested (#) | | Market Value of Shares or Units of Stock That Have Not Vested (3) ($) |
| Laura A. Francis | Laura A. Francis | | 05/26/15 | | 92,392 | | — | | | 4.32 | | 05/25/25 | | — | | | — | | Laura A. Francis | | 07/26/16 | | 05/26/15 | | 92,392 | | — | | | 4.32 | | 05/25/25 | | — | | | — | | | — | | | — | |
| 09/06/17 | | 11,277 | | — | | | 4.68 | | 03/01/27 | | — | | | — | | | 12/12/17 | | 09/06/17 | | 11,277 | | — | | | 4.68 | | 03/01/27 | | — | | | — | | | — | | | — | |
| 01/15/19 | | 2,058 | | | 13,379 | | 22.00 | | | 01/15/29 | | 7,125 | | 158,246 | | | 01/15/19 | | 01/15/19 | | 14,408 | | | 1,029 | | 22.00 | | | 01/15/29 | | 1,425 | | 19,380 | | | — | | | — | |
| — | | — | | | — | | | — | | | — | | | 8,750 | | 194,338 | | | 07/24/19 | | 08/15/19 | | — | | | — | | | — | | | — | | | 3,750 | | 51,000 | | | — | | | — | |
| — | | — | | | — | | | — | | | — | | | 28,714 | | 637,738 | | | 01/03/20 | | 01/01/20 | | — | | | — | | | — | | | — | | | 15,201 | | 206,734 | | | — | | | — | |
| — | | — | | | — | | | — | | | — | | | 40,040 | | 889,288 | | | 01/05/21 | | 01/01/21 | | — | | | — | | | — | | | — | | | 27,720 | | 376,992 | | | — | | | — | |
| Laura A. Francis | | | 04/18/21 | | 05/15/21 | | — | | | — | | | — | | | — | | | 20,540 | | 279,344 | | | — | | | — | |
| | 01/07/22 | | 01/01/22 | | — | | | — | | | — | | | — | | | 51,890 | | 705,704 | | | 127,728 | | 1,737,101 | |
| | — | | — | | | — | | | — | | | — | | | 100 | | 2,221 | | | | |
| | — | | — | | | — | | | — | | | — | | | 28,756 | | 638,671 | | |
| | Anthony J. Recupero | | 07/26/16 | | 07/05/16 | | 99,190 | | — | | | 4.32 | | 07/26/26 | | — | | | — | | | — | | | — | |
| | 12/12/17 | | 09/06/17 | | 53,943 | | — | | | 4.68 | | 03/01/27 | | — | | | — | | | — | | | — | |
| Anthony J. Recupero | | 07/05/16 | | 99,190 | | — | | | 4.32 | | 07/26/26 | | — | | | — | | | 01/15/19 | | 01/15/19 | | 41,810 | | 890 | | 22.00 | | 01/15/29 | | 1.231 | | | 16,742 | | | — | | | — | |
| Anthony J. Recupero | | 09/06/17 | | 53,943 | | — | | | 4.68 | | 03/01/27 | | — | | | — | | | 01/03/20 | | 01/01/20 | | — | | | — | | | — | | | — | | | 15,201 | | 206,734 | | | — | | | — | |
| 01/15/19 | | 31,135 | | 11,565 | | 22.00 | | 01/15/29 | | 6,156 | | 136,725 | | | 01/05/21 | | 01/01/21 | | — | | | — | | | — | | | — | | | 27,720 | | 376,992 | | | — | | | — | |
| — | | — | | | — | | | — | | | — | | | 28,714 | | 637,738 | | | 04/19/21 | | 05/15/21 | | — | | | — | | | — | | | — | | | 6,420 | | 87,312 | | | — | | | — | |
| — | | — | | | — | | | — | | | — | | | 40,040 | | 889,288 | | | 01/06/22 | | 01/01/22 | | — | | | — | | | — | | | — | | | 56,607 | | 769,855 | | | — | | | — | |
| | — | | — | | | — | | | — | | | — | | | 8,988 | | 199,623 | | | | 06/15/22 | | 06/15/22 | | — | | | — | | | — | | | — | | | 100 | | 1,360 | | | — | | | — | |
| | Anshul Maheshwari | Anshul Maheshwari | | — | | — | | | — | | | — | | | — | | | 38,240 | | 849,310 | | Anshul Maheshwari | | 04/21/21 | | 05/15/21 | | — | | | — | | | — | | | — | | | 23,900 | | 325,040 | | | — | | | — | |
| Anshul Maheshwari | | | 01/06/22 | | 01/01/22 | | — | | | — | | | — | | | — | | | 33,964 | | 461,910 | | | 27,868 | | 379,005 | |
|
(1) Shares are subject to vesting as to 1/48 of the option vests in equal monthly installments over four years commencing onaward upon continued service through each month following the vesting commencement date, specified above, subject tothrough the continued service with us through each relevantfourth anniversary of the vesting commencement date.
(2) The unvested shares subject to these options are subject to accelerated vesting in the event of a change of control of the company, in the case of Mr. Dunn, and termination of the award recipient’s employment in connection with a change of control of the company in the case of Ms. Francis and Mr. Recupero.company.
(3) For purposes of determining market value, we assumed a stock price of $22.21,$13.60, the closing sale price per share of our common stock on December 31, 2021,2022, the last business day of our last fiscal year.
PENSION BENEFITS(4) This represents the maximum number of issuable shares under the awards. The target number of shares is 50% of the maximum shares.
Pension Benefits
Our Named Executive Officers did not participate in, or otherwise receive any benefits under, any pension or retirement plan sponsored by us during 2021.
NONQUALIFIED DEFERRED COMPENSATIONNonqualified Deferred Compensation
Our Named Executive Officers did not participate in, or earn any benefits under, a nonqualified deferred compensation plan sponsored by us during 2021.2022.
SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS
Securities Authorized for Issuance Under Equity Compensation Plans
The following table shows certain information with respect to all of our equity compensation plans in effect as of December 31, 2021.2022.
| | | Plan Category | Plan Category | | Number of securities to be issued upon exercise of outstanding
stock options and awards
(a) | | Weighted-average exercise price of outstanding
stock options and awards
(b) | | | Number of securities remaining available for issuance under equity
compensation plans (excluding securities reflected in column (a) | | | Plan Category | | Number of securities to be issued upon exercise of outstanding
stock options and awards
(a) | | Weighted-average exercise price of outstanding
stock options and awards
(b) | | | Number of securities remaining available for issuance under equity
compensation plans (excluding securities reflected in column (a) | | |
Equity compensation plans approved by stockholders(1)(2) | Equity compensation plans approved by stockholders(1)(2) | | 3,576,035 | | | 4.91(2) | | | 4,404,257 | | (3)(4) | | Equity compensation plans approved by stockholders(1)(2) | | 3,853,865 | | | 4.36 | | | 5,079,492 | | (3)(4) | |
| Equity compensation plans not approved by stockholders | Equity compensation plans not approved by stockholders | | — | | | — | | | | — | | | | Equity compensation plans not approved by stockholders | | — | | | — | | | | — | | | |
| Total | Total | | 3,576,035 | | | | | | 4,404,257 | | | | Total | | 3,853,865 | | | | | | 5,079,492 | | | |
(1) The equity compensation plans approved by security holders are described in Note 10 to our financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021.2022.
(2) The weighted-average exercise price includes 1,566,5221,950,524 shares issuable upon vesting of outstanding awards of restricted stock units and performance-based restricted stock unit awards, which have no exercise price. Excluding these awards of restricted stock units, the weighted-average exercise price would be $8.73.$8.82.
(3) Includes 3,520,1024,029,313 and 884,1551,050,179 shares of common stock available for issuance under the 2018 Equity Incentive Plan, or the 2018 Plan, and the 2018 Employee Stock Purchase Plan, or the ESPP, respectively, as of December 31, 2021.2022. The shares issuable pursuant to our ESPP are not included in the number of shares to be issued pursuant to rights outstanding and the weighted-average exercise price of such rights as of December 31, 2021,2022, as those numbers are not known.
(4) The reserve for shares available under the 2018 Plan automatically increases on January 1st each year, through and including January 1, 2028, in an amount equal to 5% of the total number of shares of our capital stock outstanding on the last day of the preceding fiscal year, or a lesser number of shares as determined by the Board of Directors. The reserve for shares available under the ESPP automatically increases on January 1st of each year through and including January 1, 2028, in an amount equal to the lesser of (i) 1% of the total number of shares of common stock outstanding on such December 31, (ii) 555,000 shares of common stock, or (iii) a number of shares as determined by the Board prior to the beginning of each year.
COMPENSATION OF NON-EMPLOYEE BOARD MEMBERSCompensation of Non-Employee Board Members
The following table shows for the fiscal year ended December 31, 2021,2022, certain information with respect to the compensation of all non-employee directors of SI-BONE and Mr. Dunn:
| | Name | Name | | Fees Earned or Paid in Cash(1) | | Stock Awards(2) | | Total | Name | | Fees Earned or Paid in Cash(1) | | Non-Equity Incentive Plan Compensation | | Stock Awards(2) | | Total |
| Timothy E. Davis, Jr. | Timothy E. Davis, Jr. | | $ | 51,493 | | | $ | 121,097 | | | $ | 172,590 | | Timothy E. Davis, Jr. | | $ | 71,250 | | | | | $ | 106,797 | | | $ | 178,047 | |
| Mark J. Foley | | 2,667 | | | — | | | 2,667 | | |
Jeffrey W. Dunn (3) | | Jeffrey W. Dunn (3) | | 309,000 | | | 303,438 | | | 545,980 | | | 1,158,418 | |
| John G. Freund, M.D. | John G. Freund, M.D. | | 25,556 | | | 121,097 | | | 146,653 | | John G. Freund, M.D. | | 49,000 | | | 106,797 | | | 155,797 | |
| Jeryl L. Hilleman | Jeryl L. Hilleman | | 42,778 | | | 121,097 | | | 163,875 | | Jeryl L. Hilleman | | 67,500 | | | 106,797 | | | 174,297 | |
| Gregory K. Hinckley | Gregory K. Hinckley | | 28,167 | | | 121,097 | | | 149,264 | | Gregory K. Hinckley | | 51,250 | | | 106,797 | | | 158,047 | |
| Karen A. Licitra | | 2,667 | | | — | | | 2,667 | | |
| Helen Loh | Helen Loh | | 22,778 | | | 293,026 | | | 315,804 | | Helen Loh | | 47,500 | | | 106,797 | | | 154,297 | |
| Mika Nishimura | Mika Nishimura | | 23,333 | | | 252,612 | | | 275,945 | | Mika Nishimura | | 49,000 | | | 106,797 | | | 155,797 | |
| Keith C. Valentine | Keith C. Valentine | | 30,000 | | | 121,097 | | | 151,097 | | Keith C. Valentine | | 52,500 | | | 106,797 | | | 159,297 | |
(1) Payments earned for services rendered in the fourth quarter of 20212022 were paid in January 2022.2023.
(2) Represents the aggregate grant date fair value of restricted stock unit awards (“RSUs”) granted to the non-employee director, computed in accordance with FASB ASC Topic 718. The fair value of the RSU grant is based on the market price of our common stock on the date of grant. See Note 2 to our financial statements in our Annual Report on Form 10-K, filed with the SEC on March 1, 2022.2, 2023. Only one RSU was granted to each non-employee director during 2021, except2022.
(3) Cash compensation of our Executive Chair is paid as follows: Ms. Lohsalary. In January 2023, Mr. Dunn also received a pro-rated initial director award of 8,213 RSUs and a pro-ratedan annual award grant of 234 RSUs on April 18, 2021,bonus under the effective date of her appointment to the Board, with a grant date fair valueCorporate Bonus Plan for each RSU of $34.69; and Ms. Nishimura received a pro-rated initial director award of 8,213 RSUs and a pro-rated annual award grant of 447 RSUs on March 4, 2021, the effective date of her appointment to the Board, with a grant date fair value for each RSU of $29.17.2022.
The table below lists the aggregate number of shares subject to outstanding stock awards held by each of our non-employee directors and Mr. Dunn as of December 31, 2021.2022.
| | Name | Name | | Number of Shares
Subject to
Outstanding
Options as of
December 31, 2021 | | Number of Shares
Subject to
Outstanding
RSUs as of
December 31, 2021 | Name | | Number of Shares
Subject to
Outstanding
Options as of December 31, 2022 | | Number of Shares
Subject to
Outstanding
RSUs as of December 31, 2022 |
| Timothy E. Davis, Jr. | Timothy E. Davis, Jr. | | 71,138 | | | 3,848 | | Timothy E. Davis, Jr. | | 71,138 | | | 8,324 | |
| Jeffrey W. Dunn | | Jeffrey W. Dunn | | 687,754 | | | 95,664 | |
| John G. Freund, M.D. | John G. Freund, M.D. | | 37,963 | | | 3,848 | | John G. Freund, M.D. | | 37,963 | | | 8,324 | |
| Jeryl L. Hilleman | Jeryl L. Hilleman | | 26,236 | | | 3,848 | | Jeryl L. Hilleman | | 26,236 | | | 8,324 | |
| Gregory K. Hinckley | Gregory K. Hinckley | | 18,826 | | | 3,848 | | Gregory K. Hinckley | | 18,826 | | | 8,324 | |
| Helen Loh | Helen Loh | | — | | | 6,844 | | Helen Loh | | — | | | 12,431 | |
| Mika Nishmura | Mika Nishmura | | — | | | 6,610 | | Mika Nishmura | | — | | | 11,746 | |
| Keith C. Valentine | Keith C. Valentine | | 37,963 | | | 3,848 | | Keith C. Valentine | | 37,963 | | | 8,324 | |
NON-EMPLOYEE DIRECTOR COMPENSATION POLICYNon-Employee Director Compensation Policy
We have adopted a non-employee director compensation policy, pursuant to which our non-employee directors will be eligible to receive cash compensation for service on our Board and committees of our Board.
Each non-employee director receives an annual cash retainer of $40,000$45,000 for serving on our Board.
The chairperson and members of the three committees of our Board are entitled to the following annual cash retainers:
| | Board Committee | Board Committee | | Chairperson Fee | | Member Fee | Board Committee | | Chairperson Fee | | Member Fee |
| Audit Committee | Audit Committee | | $ | 20,000 | | | $ | 7,500 | | Audit Committee | | $ | 20,000 | | | $ | 10,000 | |
| Compensation Committee | Compensation Committee | | 15,000 | | 6,000 | Compensation Committee | | 15,000 | | 7,000 |
| Nominating and Corporate Governance Committee | Nominating and Corporate Governance Committee | | 10,000 | | 5,000 | Nominating and Corporate Governance Committee | | 10,000 | | 5,000 |
| Lead Independent Director | Lead Independent Director | | 5,000 | | — | | Lead Independent Director | | 5,000 | | — | |
| Chair of the Board | | Chair of the Board | | 45,000 | | — | |
All annual cash compensation amounts are payable in equal quarterly installments in arrears, on the last day of each fiscal quarter for which the service occurred, pro-rated based on the days served in the applicable fiscal quarter.
Each new non-employee director who joins our Board will receive a restricted stock unit award with a value of $225,000.$200,000. The shares subject to these equity awards will vest ratably over 36 months, subject to the non-employee director’s continuous service with us on each applicable vesting date.
In addition, under the policy, on the date of each annual meeting of our stockholders, each continuing non-employee director may receive a restricted stock unit award with a value of $120,000, vesting approximately one year from the grant date, subject to the non-employee director’s continuous service with us on each applicable vesting date.
In the event of a change of control (as defined in the 2018 Plan), any unvested shares subject to these equity awards will fully vest and, in the case of stock options become exercisable, immediately prior to the effective date of such change of control, subject to the non-employee director’s continuous service with us on the effective date of the change of control.
Compensation of Executive Chair
In 2022, our Jeffrey Dunn served as our Executive Chairman, pursuant to the Amendment dated January 5, 2021 to the Offer Letter Agreement dated December 15, 2009 and the Severance Plan Participation (the "Executive Chairman Agreement"). Pursuant to the Executive Chairman Agreement, Mr. Dunn devoted 50% of his business time to the affairs of the company, including leadership of our Board, and was paid a salary equal to approximately 50% of his salary effective immediately prior to his transition from Chief Executive Officer of the company to Executive Chair of the company in April 2021. In addition, in January 2022, our Compensation Committee approved the grant of a restricted stock unit to Mr. Dunn, vesting quarterly over the four years following the date of grant. Mr. Dunn was also eligible to participate in our annual Corporate Bonus Plan in 2022, with a target bonus amount of 100% of the salary earned in the same period, with achievement based on corporate performance, consistent with our named executive officers. Mr. Dunn will continue to serve as Executive Chairman of our Board until May 1, 2023, at which point he will become Chair of the Board and will be compensated according to our non-employee director compensation policy described above.
Pay Versus Performance
The compensation actually paid disclosed below for our Principal Executive Officer (“PEO”) and the average of our non-PEO named executive officers “Non-PEO NEOs” was calculated in accordance with the requirements of Item 402(v) of Regulation S-K. The compensation actually paid figures presented in the table below incorporate total executive compensation as reported in the Summary Compensation Table adjusted for changes in the fair value of equity awards (we do not have any pension benefits). Accordingly, compensation actually paid does not equate to the amount that is actually paid to any executive in a given year and is merely a measurement determined by the SEC in an effort to identify the relationship between executive compensation and our financial performance.
The following table sets forth the compensation actually paid to our PEO and average of our Non-PEO NEOs, serving in such capacity, along with certain measures of our performance in each of the two years ended December 31, 2022 and December 31, 2021:
| | | | | | | | | | | | | | | | | | | | | | | | | | |
Year(1) | Summary Compensation Table Total for PEO#1(2) | Compensation Actually Paid to PEO#1(3) | Summary Compensation Table Total for PEO#2(4) | Compensation Actually Paid to PEO#2(5) | Average Summary Compensation Table Total for Non-PEO NEOs(6) | Average Compensation Actually Paid to Non-PEO NEOs(7) | Value of Initial Fixed $100 Investment Based On: | Net Loss (millions)(9) |
Total Shareholder Return(8) |
| 2022 | $ | — | | $ | — | | $ | 4,893,959 | | $ | 2,616,198 | | $ | 2,243,715 | | $ | 1,185,889 | | $ | 45 | | $ | (61.3) | |
| 2021 | $ | 4,347,631 | | $ | 1,058,832 | | $ | 3,430,641 | | $ | 2,203,680 | | $ | 2,075,023 | | $ | 1,418,469 | | $ | 74 | | $ | (56.6) | |
________________
(1) We are a smaller reporting company and, accordingly, we have not included any information in this table for 2020.
(2) The dollar amounts represent the amounts of total compensation reported for Mr. Dunn (our former CEO) for 2021 in the “Total” column of the Summary Compensation Table in our prior year's proxy statement.
(3) The dollar amounts represent the amount of “compensation actually paid” to Mr. Dunn, as computed in accordance with Item 402(v) of Regulation S-K. The dollar amounts do not reflect the actual amount of compensation earned by or paid to Mr. Dunn during the applicable year. In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to Mr Dunn’s total compensation for 2021 to determine the compensation actually paid:
| | | | | | | | | | | | | | | | | | | | | | | |
| Year | Summary Compensation Table Total | Minus Stock and Option Awards from Summary Compensation Table | Plus Year-End Equity Value of Unvested Awards Granted During Year | Plus Change in Value of Unvested Awards Granted in Prior Years | Plus Value of Awards Granted and Vested During Year | Plus Change in Value of Prior Years' Awards Vested During Year | Compensation Actually Paid |
|
| 2021 | $ | 4,347,631 | | $ | (3,599,820) | | $ | 1,137,019 | | $ | (1,041,880) | | $ | 488,973 | | $ | (273,091) | | $ | 1,058,832 | |
(4) The dollar amounts represent the amounts of total compensation reported for Ms. Francis (our current CEO) for each corresponding year in the “Total” column of the Summary Compensation Table. Refer to “Executive Compensation—Summary Compensation Table.”
(5) The dollar amounts represent the amount of “compensation actually paid” to Ms. Francis, as computed in accordance with Item 402(v) of Regulation S-K. The dollar amounts do not reflect the actual amount of compensation earned by or paid to Ms. Francis during the applicable year. In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to Ms. Francis’s total compensation for each year to determine the compensation actually paid:
| | | | | | | | | | | | | | | | | | | | | | | |
| Year | Summary Compensation Table Total | Minus Stock and Option Awards from Summary Compensation Table | Plus Year-End Equity Value of Unvested Awards Granted During Year | Plus Change in Value of Unvested Awards Granted in Prior Years | Plus Value of Awards Granted and Vested During Year | Plus Change in Value of Prior Years' Awards Vested During Year | Compensation Actually Paid |
|
| 2022 | $ | 4,893,959 | | $ | (3,785,800) | | $ | 2,157,221 | | $ | (596,449) | | $ | 214,756 | | $ | (267,489) | | $ | 2,616,198 | |
| 2021 | $ | 3,430,641 | | $ | (2,550,899) | | $ | 1,530,180 | | $ | (439,338) | | $ | 350,481 | | $ | (117,385) | | $ | 2,203,680 | |
(6) The dollar amounts represent the average of the amounts reported for our named executive officers (“NEOs”) as a group (thus excluding each of Mr. Dunn, who served as our CEO for a portion of 2021, and Ms. Francis, who has served as our CEO for a portion of 2021 and all of 2022) in the “Total” column of the Summary Compensation Table in each applicable year. The Non-PEO NEOs included for purposes of calculating the average amounts in each applicable year were Mr. Maheshwari and Mr. Recupero.
(7) The dollar amounts represent the average amount of “compensation actually paid” to the Non-PEO NEOs as a group, as computed in accordance with Item 402(v) of Regulation S-K. The dollar amounts do not reflect the actual average amount of compensation earned by or paid to the Non-PEO NEOs as a group during the applicable year. In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to average total compensation for the Non-PEO NEOs as a group for each year to determine the compensation actually paid, using the same methodology described above in footnote 3:
| | | | | | | | | | | | | | | | | | | | | | | |
| Year | Avg. Summary Compensation Table Total | Minus Avg. Stock and Option Awards from Summary Compensation Table | Plus Avg. Year-End Equity Value of Unvested Awards Granted During Year | Plus Avg. Change in Value of Unvested Awards Granted in Prior Years | Plus Avg. Value of Awards Granted and Vested During Year | Plus Avg. Change in Value of Prior Years' Awards Vested During Year | Avg. Compensation Actually Paid |
|
| 2022 | $ | 2,243,715 | | $ | (1,538,932) | | $ | 775,142 | | $ | (322,978) | | $ | 187,412 | | $ | (158,470) | | $ | 1,185,889 | |
| 2021 | $ | 2,075,023 | | $ | (1,547,509) | | $ | 969,111 | | $ | (175,806) | | $ | 145,490 | | $ | (47,840) | | $ | 1,418,469 | |
(8) Cumulative TSR is calculated by dividing a fixed investment of $100 at the beginning of the measurement period (December 31, 2020) into a number of shares by the value of that investment at the end of the measurement period plus the cumulative amount of dividends for the measurement period, assuming dividend reinvestment. "Measurement period" is defined as: for 2021, the one-year period from market close on December 31, 2020 through December 31, 2021; and for 2022, the two-year period from market close on December 31, 2020 through December 30, 2022.
(9) The dollar amounts reported represent the amount of net loss reflected in our audited financial statements for the applicable year.
Financial Performance Measures
As described in above, our executive compensation program reflects a variable pay-for-performance philosophy. The metrics that we use for both our long-term and short-term incentive awards are selected based on an objective of incentivizing our NEOs to increase the value of our enterprise for our shareholders. The most important financial performance measures used by us to link executive compensation actually paid to our NEOs, for the most recently completed fiscal year, to our performance are as follows:
•Revenue
•Relative TSR, as described in the Long-Term Incentive Compensation section of the Executive Compensation narrative above
•Adjusted EBITDA, as defined in the Overview to the Executive Compensation narrative above
Analysis of the Information Presented in the Pay Versus Performance Table
As described in more detail above, our executive compensation program reflects a variable pay-for-performance philosophy. While we utilize several performance measures to align executive compensation with our performance, not all of those company measures are presented in the Pay Versus Performance table. Moreover, we generally seek to incentivize long-term performance, and therefore do not specifically align our performance measures with compensation that is actually paid (as computed in accordance with Item 402(v) of Regulation S-K) for a particular year. In accordance with Item 402(v) of Regulation S-K, we are providing the following descriptions of the relationships between information presented in the Pay Versus Performance table, as well as compensation actually paid as compared to our revenue.
Compensation Actually Paid and Cumulative TSR
The following graph shows the relationship between compensation actually paid and TSR. TSR shows the cumulative total return on an investment of $100 in cash on December 31, 2020 through December 21, 2022, in our common stock, assuming that any dividends were reinvested. The return shown on the graph below is not necessarily indicative of future performance, and we do not make or endorse any predictions as to future stockholder returns.
Compensation Actually Paid and Net Loss
The following graph shows the relationship between compensation actually paid and Net Loss:
Compensation Actually Paid and Revenue
The following graph shows the relationship between compensation actually paid and revenue:
All information provided above under the “Pay Versus Performance” heading will not be deemed to be incorporated by reference into any filing of SI-BONE under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing, except to the extent we specifically incorporate such information by reference.
CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
RELATED PERSON TRANSACTIONS POLICY AND PROCEDURESRelated Person Transactions Policy and Procedures
Our Audit Committee has the primary responsibility for the review, approval, and oversight of any “related party transaction,” which is any transaction, arrangement, or relationship (or series of similar transactions, arrangements, or relationships) in which we are, were, or will be a participant and the amount involved exceeds $120,000, and in which the related person has, had, or will have a direct or indirect material interest.
We have adopted a written related party transaction policy under which our management is required to submit any related person transaction not previously approved or ratified by our Audit Committee to our Audit Committee. In approving or rejecting the proposed transactions, our Audit Committee will take into account all of the relevant facts and circumstances available. Our Audit Committee will approve only those transactions that, as determined by our Audit Committee, are in, or are not inconsistent with, our best interests and the best interests of our stockholders.
CERTAIN RELATED PERSON TRANSACTIONSCertain Related Person Transactions
The following is a description of transactions since January 1, 2020,2021, to which we have been a party in which the amount involved exceeded the lesser of $120,000 or one percent of our total assets at year end for the last two completed fiscal years and in which any of our executive officers, directors, promoters, or beneficial holders of more than 5% of our capital stock had or will have a direct or indirect material interest, other than compensation arrangements discussed above.
Joint Development Agreement with SeaSpine Orthopedics Corporation
InOn February 24, 2020, we entered into a joint development agreement (the “Development Agreement”) with SeaSpine Orthopedics Corporation (“SeaSpine”SeaSpine”), which recently merged with Orthofix Medical, Inc., to develop a next generation device for sacropelvic fixation. Mr. Keith Valentine, who serves as the President, Chief Executive Officer and a member of the board of directors of SeaSpine, also serves as a member of our Board of Directors. PursuantBoard. On April 27, 2021, Addendum No.1 to the development plan,Development Agreement was entered into by and between us and SeaSpine shall use reasonable efforts to assist inextend certain obligations as described under the development of the potential product offering, including licensing certain existing intellectual property to be incorporated into the product. Development Agreement.
Under the terms of the Development Agreement, we agreed to make monthly payments of approximately $10,000 to SeaSpine to reimburse for full time resources employed by SeaSpine responsible for conducting the development activities duringactivities. For the period in which such development activities occurred.years ended December 31, 2022 and 2021, we expensed $38,725 and $29,000, respectively, of reimbursement charges from SeaSpine. Certain intellectual property developed pursuant to the project plan will be owned by us, certain intellectual property developed pursuant to the project plan will be owned by SeaSpine, and other intellectual property developed pursuant to the project plan will be jointly owned by SeaSpine and us. We also agreed to provide SeaSpine a royalty-free, worldwide, perpetual, non-exclusive license of certain of our intellectual property incorporated into the product to be developed. We also agreed to pay SeaSpine a product royalty, in an amount specified in the Development Agreement, for each resulting product sold for a period of 10 years beginning on the initial market launch. The term of the Development Agreement shall continue until the expiration of all royalty terms, unless earlier terminated by either parties, in situations defined in the Development Agreement.
2020 Public Offering
In January 2020, we issued and sold shares of common stock in an underwritten public offering (the “First 2020 Public Offering”). Each of Skyline Venture Partners V., L.P., (“Skyline”), Montreux IV, L.P. (“Montreux”) and Arboretum Ventures IV, L.P. (“Arboretum,” and collectively with Skyline and Montreux, the “Selling Stockholders”) sold shares in the offering. Each of the Selling Stockholders held more than 5% of our capital stock at the time of the First 2020 Public Offering, and Dr. Freund is a managing partner of Skyline Ventures, an affiliate of Skyline. In connection with the First 2020 Public Offering, we, the representatives of the underwriters, and the Selling Stockholders entered into an underwriting agreement pursuant to which Skyline, Montreux and Arboretum sold 1,000,000, 649,947 and 160,000 shares, respectively, for approximately $21,500,000, $13,973,860 and $3,440,000, respectively, before underwriting discounts and commissions.
In October 2020, we issued and sold shares of common stock in an underwritten public offering (the “Second 2020 Public Offering”) in which Skyline sold 190,053 shares for approximately $4,181,166, before underwriting discounts and commissions. Skyline held more than 5% of our capital stock at the time of the Second 2020 Public Offering, and Dr. Freund is a managing partner of Skyline Ventures, an affiliate of Skyline.
INDEMNIFICATION AGREEMENTS
Our amended and restated certificate of incorporation contains provisions limiting the liability of directors, and our amended and restated bylaws provide that we will indemnify each of our directors to the fullest extent permitted under Delaware law. Our amended and restated certificate of incorporation and amended and restated bylaws also provide our Board with discretion to indemnify our officers and employees when determined appropriate by our Board.
We have and intend to enter into indemnification agreements with each of our directors and executive officers and certain other key employees. The indemnification agreements provide that we will indemnify each of our directors, executive officers, and such other key employees against any and all expenses incurred by that director, executive officer, or other key employee because of his or her status as one of our directors, executive officers, or other key employees, to the fullest extent permitted by Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws. In addition, the indemnification agreements provide that, to the fullest extent permitted by Delaware law, we will advance all expenses incurred by our directors, executive officers and other key employees in connection with a legal proceeding involving his or her status as a director, executive officer or employee.
HOUSEHOLDING AND PROXY MATERIALS
The SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for Annual Meeting materials with respect to two or more stockholders sharing the same address by delivering a single set of Annual Meeting materials addressed to those stockholders. This process, which is commonly referred to as “householding,” potentially means extra convenience for stockholders and cost savings for companies.
This year, a number of brokers with account holders who are SI-BONE, Inc. stockholders will be “householding” SI-BONE’s proxy materials. A single set of Annual Meeting materials will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker that they will be “householding” communications to your address, “householding” will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in “householding” and would prefer to receive a separate set of Annual Meeting materials, please notify your broker or SI-BONE, Inc. Direct your written request to SI-BONE, Inc, Attn: Michael A. Pisetsky, Chief Legal Officer,General Counsel, 471 El Camino Real, Suite 101, Santa Clara, California 95050. Stockholders who currently receive multiple copies of the Annual Meeting materials at their addresses and would like to request “householding” of their communications should contact their brokers.
OTHER MATTERS
The Board of Directors knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are properly brought before the meeting, it is the intention of the persons named in the accompanying proxy to vote, to the extent permitted under Rule 14a-4(c)(1) under the Exchange Act, on such matters in accordance with their best judgment.
By Order of the Board of Directors
| | |
| /s/ Michael A. Pisetsky |
| Michael A. Pisetsky |
Secretary and Chief Legal OfficerGeneral Counsel |
|
April 22, 202221, 2023
A copy of SI-BONE, Inc.’s Annual Report to the Securities and Exchange Commission on Form 10-K for the fiscal year endedending December 31, 20212022 is available without charge upon written request to: Corporate Secretary, SI-BONE, Inc, 471 El Camino Real, Suite 101, Santa Clara, California 95050.
